“You Choose” Leadership Award Application September 22, 2014 Elizabeth R. Smith, Ph.D. Research Assistant Professor Department of Cell Biology Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Office Address: 415 Papanicolaou Building [M877] 1550 NW 10th Avenue Miami, FL 33136 Office Phone: 305-243-1433 Email: esmith@med.miami.edu

Training in Ovarian Granulosa Cell Biology Abstract: The aim of the proposed project is to obtain training and establish collaborations with an expert researcher in granulosa cell and ovarian cancer biology. Observations from some of my recent studies suggest that granulosa cells regulate ovarian surface and perhaps fallopian epithelial cell proliferation, which may be an important mechanism to explain the association of ovarian cancer risk and age. Our slow progress in understanding the mechanism has been stymied by a lack of experience and expertise in granulosa cell biology. Here, we will obtain training and establish useful contacts with an expert in ovarian follicle, granulosa cell, and ovarian cancer biology. I expect to use the training to develop this area into an independent research focus. Activity goals: For a number of years, my research has focused on understanding the association between age and the risk of ovarian cancer. Most ovarian cancers are epithelial in origin, and most of these are diagnosed in women over the age of 50, or in the post-menopause years. We have studied a mouse model that mimics many features of menopause, including follicle depletion and long post-reproductive lifespan, elevated gonadotropins, lowered steroid hormones, changes in lipid profiles, and bone and cardiac changes. In this, as well as other menopausal models, depletion of follicles stimulates epithelial proliferation. I speculate that a follicle-derived factor, most likely produced by the granulosa cells, may be involved in regulating epithelial growth. It is this hypothesis that I would really like to pursue. I would like to establish the procedures for co-culturing granulosa cells with ovarian and fallopian tube epithelial cells. My lab has made preliminary forays into this area, which have led me to conclude that it would be most expedient to go to the expert. I have recently contacted Dr. Barbara Vanderhyden of the University of Ottawa. Dr. Vanderhyden is an expert in ovarian cancer research and has a strong research program in basic ovarian biology. As a post-doc, she trained in the area of follicle biology, in particular the interactions between oocyte and granulosa cells, and has knows how to propagate both co-cultures of ooctyes and granulosa cells, as well as solely granulosa cell cultures. I propose that our laboratory technician and I visit Dr. Vanderhyden’s lab in Ottawa for at least 2 days to be trained in collecting and culturing murine granulosa cells. Dr. Vanderhyden has graciously agreed to share her own expertise as well as her technician’s time to help us (please see attached letter of support). We expect to learn the following: how to prime the mouse to give the best yield of follicles; how to isolate the follicles from the ovaries; how to isolate the granulosa cells; and how to co-culture ovarian epithelial and granulosa cells. This training will be incredibly valuable in strengthening our research and making it much more viable for extramural funding. I hope also that the onsite visit will foster the exchange of ideas and collaborations. Personal goals: I would like to continue to explore the mechanisms related to the etiology of ovarian cancer, especially the association between age and risk. To do this, and provide some needed security to my non-tenured position, I should obtain extramural funding. I believe the training supported by this You Choose! Award will be most beneficial. It will permit the lab to get the experiments optimized and running quickly and get important preliminary data to support our hypothesis, which is important. Additionally, this is a wonderful opportunity to interact with a well-respected ovarian biologist and cancer researcher.

Budget and budget justification: Funds are requested to visit Dr. Barbara Vandherhyden’s lab at the Ottawa Hospital Research Institute of the University of Ottawa. The budget is based on the cost of two round-trip airfares from Miami to Ottawa, hotel accommodations for three nights, food, and transportation, as well as supplies that will be used for experiments in Dr. Vanderhyden’s lab. Airfare: The average price for an economy round-trip ticket from Miami to Ottawa varies from Monday to Saturday, with the average cost of $550-600. We will try to book the most economical flight, which usually is for Wednesday to Saturday. Based on this, we would propose to travel on Wednesday, work in the lab on Thursday and Friday, and return Saturday. However, the actual dates of the visit will be made at Dr. Vanderhyden’s and her lab staff’s convenience. The maximum expected cost of airfare, inclusive of flight charges and taxes and transportation from the Ottawa airport, should be $1300. Hotel: We will stay in a hotel near the University of Ottawa campus, within walking distance of Dr. Vanderhyden’s lab. The average cost per night is $150. The expected cost of the hotel, inclusive of taxes, should be $500. Food: The University of Miami permits $50 per diem for food expenses during travel. Based on this rate, the cost of food for two persons should be $400. Other expenses: We will reimburse the Vanderhyden lab for supplies used for instruction. Based on similar experiments in our lab, we expect the costs to total $300. Expected total cost: $2500.

Elizabeth R. Smith Department of Cell Biology Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami, FL 33136 Office: (305)243-1433 esmith@med.miami.edu Professional Preparation Transylvania University, Lexington, KY Biology & English B.A. Summa cum laude, 1988 Emory University, Atlanta, GA Biochemistry Ph.D., 1994 Rutgers University, New Brunswick, NJ Nutritional Science 1994-1996 Emory University, Atlanta, GA Rad. Oncol. & Biochemistry 1996-1998 Appointments 2011-present Research Assistant Professor, Department of Cell Biology, University of Miami 2007-2011 Research Assistant Professor, Department of Medicine, University of Miami 2007 Assistant Member, Fox Chase Cancer Center 2000-2007 Staff Scientist, Fox Chase Cancer Center 1998 Visiting Assistant Professor, Agnes Scott College Publications i. Five most closely related to proposal project 1. Smith ER, Wang Y, Xu XX. Development of a mouse model of menopausal ovarian cancer. Front

Oncol. 4:36, 2014. 2. Smith ER, Yang WL, Yeasky T, Smedberg J, Cai KQ, Xu XX. Cyclooxygenase-1 inhibition prolongs

postnatal ovarian follicle lifespan in mice. Biol Reprod. 89(4):103, 2013. 3. Smith ER, Yeasky T, Wei JQ, Miki RA, Cai KQ, Smedberg JL, Yang WL, Xu XX. White spotting

variant mouse as an experimental model for ovarian aging and menopausal biology. Menopause. 19(5):588-596, 2012.

4. Smith ER, and Xu XX. Ovarian aging, follicle depletion, and cancer: a hypothesis for the etiology of epithelial ovarian cancer involving follicle depletion. Lancet Oncol. 9:1108-1111, 2008.

5. Yang WL, Cai KQ, Smedberg JL, Smith ER, Klein-Szanto A, Hamilton TC, and Xu XX. A reduction of cyclooxygenase-2 gene dosage counters the ovarian morphological aging and tumor phenotype in Wv mice. Am J Pathol. 170:1325-1336, 2007.

ii. Five other significant publications 1. Moore R, Tao W, Smith ER, Xu XX. The primitive endoderm segregates from the epiblast in β1

integrin-deficient early mouse embryos. Mol Cell Biol. 34:560-572, 2014. 2. Capo-chichi CD, Smith ER, Rosario S, Ganjei-Azar P, Xu XX. Nuclear envelope defects in epithelial

ovarian cancer. Am J Clin Exp Obstet Gynecol. 1(1):17-30, 2013. 3. Smith ER, Zhang XY, Capo-chichi CD, Chen X, Xu XX. Increased expression of Syne-1/Nesprin-1

facilitates nuclear envelope structure changes in embryonic stem cell differentiation. Dev Dyn. 240:2245-2255, 2011.

4. Smith ER, Cai KQ, Smedberg JL, Ribeiro MM, Rula ME, Slater C, Godwin AK, and Xu XX. Nuclear entry of activated MAPK is restricted in primary ovarian and mammary epithelial cells. PLoS ONE. 5(2):e9295, 2010.

5. Smith ER, Smedberg JL, Rula ME, and Xu XX. Regulation of Ras/MAPK mitogenic activity by restricting nuclear entry in endoderm differentiation of embryonic carcinoma and stem cells. J Cell Biol. 164:689-699, 2004.

Synergistic Activities • HHMI Teaching Partnership with Norristown Area High School (PA) (2005-2007) • Ad Hoc Reviewer (2007-present): Chemotherapy FASEB J, J Cell Science, PLOS One,

International Journal of Medical Science • Scientific Reviewer: DOD BCRP MGB-1 (2009), DOD OCRP Clinical and Experimental

Therapeutics (2012) Collaborators & Other Affiliations

• Collaborators and Co-Editors: Andrew K. Godwin (University of Kansas); Kathy Qi Cai (Fox Chase Cancer Center)

• Graduate Advisors and Postdoctoral Sponsors:

Ph.D. Advisor: Alfred H. Merrill, Jr. (Georgia Tech) Post-Doc Advisors: Judith Storch (Rutgers University), Victoria Stevens (American Cancer Society)

• Mentored students (high school & undergraduate): Jed Aronson (Rutgers University); Genevieve Vidanes (Emory University); Nicole Bush, Megan Druding, Andrew Turner (Fox Chase Cancer Center); Jessica Clark, Zeqi Wang, Justin Correa, Arn Xu, Celestina Okoye (University of Miami)

RE: collaboration and training Vanderhyden, Barbara <bvanderhyden@ohri.ca> Fri 9/19/2014 10:06 AM Inbox To: Smith, Elizabeth R <esmith@umail.miami.edu> Hello Elizabeth, It would be my pleasure to teach someone from your lab the fine points of establishing primary cultures of granulosa cells. As you know, my lab has considerable experience in the isolation and culture of granulosa cells from mice and rats. We can help sort through the key factors for consideration in the choice of the model system used and the rationale for each (eg. normally cycling vs. DES-primed vs. PMSG-primed animals) and the importance of the culture conditions to restrict spontaneous differentiation (luteinization), in addition to guidance on the best practices for cell culture (eg. ensuring sterility of primary cultures). I would be happy to discuss the details of this visit whenever it is convenient. Good luck with your application! Barbara -----­‐------------------------------------------------------------------------ Barbara Vanderhyden, Ph.D. - Corinne Boyer Chair in Ovarian Cancer Research Professor, Dept. of Cellular and Molecular Medicine, University of Ottawa Senior Scientist, Centre for Cancer Therapeutics, Ottawa Hospital Research Institute 501 Smyth Road, 3rd Floor, Box 926 Ottawa, Ontario K1H 8L6 phone: 613-737-7700 ext. 70330 fax:   613-247-3524 email: bvanderhyden@ohri.ca www.med.uottawa.ca/vanderhyden/

1

June 2014

CURRICULUM VITAE Barbara C. Vanderhyden

ADDRESS: Centre for Cancer Therapeutics, Ottawa Hospital Cancer Centre,

501 Smyth Road, Third Floor, Box 926, Ottawa, Ontario K1H 8L6 work: (613) 737-7700, ext. 70330 FAX: (613) 247-3524 E-mail: bvanderhyden@ohri.ca home: (613) 521-2074

APPOINTMENTS 07/00 - present Corinne Boyer Chair in Ovarian Cancer Research, University of Ottawa 07/01 - present Professor, Department of Cellular and Molecular Medicine, University of Ottawa 07/01 - present Cross-appointee, Department of Medicine, University of Ottawa 04/04 - present Senior Scientist, Ottawa Health Research Institute 04/98 - 03/04 Associate Scientist, Ottawa Health Research Institute 07/96 - 06/01 Associate Professor, Department of Medicine, University of Ottawa 04/95 - 03/05 Career Scientist, Ottawa Regional Cancer Centre 06/91 - present Cross-appointee, Department of Obstetrics & Gynecology, University of Ottawa

(Division of Reproductive Medicine; Division of Gynecologic Oncology) 06/91- 06/01 Cross-appointee, Department of Cellular & Molecular Medicine (formerly

Physiology), University of Ottawa 01/91 - 06/96 Assistant Professor, Department of Medicine, University of Ottawa

EDUCATION 07/88 - 12/90 Post-doctoral associate, The Jackson Laboratory

Supervisor: Dr. John J. Eppig Projects: Retroviral infection of oocytes as a novel method for the generation of transgenic mice; role of the germ cell in the regulation of somatic cell activity

05/83 - 10/88 Ph.D. (Physiology), University of Western Ontario, London

Supervisor: Dr. David T. Armstrong Thesis Title: Studies on the regulation of oocyte maturation in the rat with assessment by in vitro fertilization and fetal development.

09/79 - 05/83 B.Sc. (Honours Physiology), University of Western Ontario

RELATED WORK EXPERIENCE 1985-88 Human in vitro fertilization program - University Hospital, London, Canada

Part-time laboratory technologist: oocyte collection, in vitro fertilization, embryo transfer

2

AWARDS and RECOGNITIONS 2014 Capital Educator’s Award 2014 Governor General’s Caring Canadian Award 2010 Canadian Broadcasting Corporation’s Champions of Change: Top 50 2009 CIHR Synapse Mentorship Award, Canadian Institutes of Health Research 2009 YMCA-YWCA Woman of Distinction Award, Research category 2009 Honoured Champion, United Nations Association in Canada 2008 Outstanding Achievement Award, Let’s Talk Science 2007 Canada’s Most Powerful Women: Top 100™ award 2007 Biomedical Science Ambassador Award, Partners in Research 2005 President’s Award for Service to the University through Media and Community Relations 2004 Mentoring Award, Faculty of Medicine, University of Ottawa 2002 Award of Excellence, Faculty of Medicine, University of Ottawa 2001 Gordin Kaplan Award for Science Promotion, Canadian Federation of Biological Sciences 1999 Premier’s Research Excellence Award (Province of Ontario) 1998 Ottawa-Carleton Partnership Individual Award of Excellence, Ottawa Centre for Research & Innovation 1988-91 Medical Research Council of Canada Fellowship 1988 Collip Medal - University of Western Ontario (Highest award offered to a Ph.D. graduate in the

Faculties of Science and Medicine; based on an assessment of thesis, research potential, teaching and academic administrative involvement).

1988 Esme Walker Award - Dept. of Physiology, U.W.O. (Highest award given to a Ph.D. graduate in Dept. of Physiology).

1988 Excellence in Teaching Award - Faculty of Graduate Studies, U.W.O. 1983-87 Ontario Graduate Scholarship 1983-87 Special University Scholarship - U.W.O. 1984,85,86,88 Annual Research Day Award - Dept. of Obstetrics & Gynaecology, U.W.O. 1983 Dean's Honour List 1981,82 W.F. Thomas Bursary 1979 Entrance Scholarship - U.W.O. ADMINISTRATIVE ACTIVITIES External 2014-2015 Member, Publications Committee, Society for the Study of Reproduction 2014 Member, Grants Review Panel, Cancer Research Society, Tumour Progression and Metastasis 2013-2014 Member, Nominations Committee, Society for the Study of Reproduction 2013-present Chair, Study Committee, Canadian Ovarian Experimental Unified Resource 2013-present Member, Editorial Board, Journal of Ovarian Research 2013 Member, Grants Review Panel, Canadian Cancer Society Research Institute 2012-2013 Past President, Society for the Study of Reproduction 2012 Member, Grants Review Panel, CIHR Endocrinology 2011-2012 President, Society for the Study of Reproduction 2011 Member, Grants Review Panel, CIHR Cancer Progression and Therapeutics 2011 Member, Grants Review Panel, Canadian Cancer Society Research Institute 2011 Member, Grants Review Panel, European Commission 2010-present Member, Management Committee, Canadian Ovarian Experimental Unified Resource (COEUR) 2010-2013 Member, Study Committee, Canadian Ovarian Experimental Unified Resource 2010-2011 President-Elect, Society for the Study of Reproduction 2009-2010 Chair, Steering Committee, Oncofertility Workshop 2009 Scientific Officer, CIHR Catalyst Grants Panel 2009 Member, NIH Cellular, Molecular and Integrative Reproduction Study Section 2008-present Member, Correlative Science and Tumour Biology Committee for Gynecologic Oncology, National

Cancer Institute of Canada Clinical Trials Group 2008-2009 Member, Nominations Committee, Society for the Study of Reproduction 2008-2009 Member, Program Committee, Annual Meeting, Society for the Study of Reproduction

3

ADMINISTRATIVE ACTIVITIES (continued) External 2007, 2010 Member, Grants Review Panel for Cancer Research Society 2006, 2008 Member, U.S. Department of Defence Ovarian Cancer Research grants review panel 2006 Member, NIH Cancer Genetics and Biology Member Conflict Study Section 2006 Member, Review Panel for CIHR Team Grants Committee 2005-2008 Director, Society for the Study of Reproduction 2005-2010 Member, Board of Directors, Canadian Cancer Society, Unit Council 2005-2010 Member, Scientific Advisory Board, Genome Canada project, Université de Sherbrooke 2004-2005 Member, European Commission Grants Review Panel for ‘Combating Cancer’ 2004-present Chair, Research Committee, Ovarian Cancer Canada (formerly National Ovarian Cancer Association) 2004-present Member, Editorial Board, BMC Cancer 2004-2006 Consultant, IBEX Pharmaceuticals Inc., Montréal 2004-2009 Member, Canadian Working Group, InterAmerican Network of Academies of Sciences 2004-2005 Member, Selection Committee for the Polanyi Prize, Ontario Council on Graduate Studies 2004-2008 Member, Scientific Advisory Board, Integrative Genomics for Women’s Health, Montréal 2004-2006 Member, Scientific Advisory Board, Division of Reproductive Biology, McMaster University 2004 Member, NIH Study Section on Cellular, Molecular and Integrative Reproduction 2003-2004 Chair, Subcommittee on Outreach, Strategic Planning Committee, Society for the Study of Reproduction 2003-2008 Member, Scientific Advisory Board, Ovarian Cancer Research Program, University of South Florida 2003 Member, Review Panel for NIH RFA on “Female Health and Egg Quality” 2002-present Member, Board of Directors, Ovarian Cancer Canada (formerly National Ovarian Cancer Association) 2002-2005 Member, Awards Committee, Society for the Study of Reproduction 2001-2004 Scientific Officer, Canadian Institutes of Health Research, Cancer ‘A’ Grants Committee 2001-2004 Chair, Organizing Committee, Canadian Conference on Ovarian Cancer Research (2002, 2004) 2001-2004 Member, Advisory Committee to the Institute Advisory Board of the CIHR Institute of Human

Development, Child and Youth Health 2001-2002 Chair, Editorial Board, Challenge – Life with Cancer 2001 Member, Selection Committee, Northeastern Ontario Regional Cancer Centre 2001 Member, National Cancer Institute (U.S.) Gynecologic Cancers Progress Review Group 2000 Member, NIH Reproductive Biology Study Section 2000-2001 Panel member, Ontario Graduate Scholarship Program 2000-2001 Chair, Membership Committee, Society for the Study of Reproduction 2000 Moderator, Ottawa Life Sciences National Conference 1999-2000 Session Coordinator, Gordon Conference on Mammalian Gametogenesis and Embryogenesis 1999-2004 Member, Steering Committee, Mouse Models of Human Cancers Consortium (U.S. NCI) 1999-2009 Member, Canadian Council on Animal Care, Subcommittee on Biotechnology 1999-2002 Chair, Research Implementation Committee, National Ovarian Cancer Association 1999 Session Coordinator, Annual meeting for the Society for the Study of Reproduction 1999-2000 Co-chair, Membership Committee, Society for the Study of Reproduction 1999-2001 Member, Local Arrangements Committee, Society for the Study of Reproduction 1998-2001 Member, MRC Cancer ‘A’ Grants Committee 1998-1999 Session Coordinator and Co-chair, Northeast Regional Developmental Biology Conference 1998-1999 Member, Medical Advisory Board, Corinne Boyer Fund 1997-1998 Member, Project Evaluation Committee, Connaught Student Biotechnology Exhibition 1997-1998 Member, Outreach Committee, Society for the Study of Reproduction 1997 Assessment panel member, Canadian Council on Animal Care (CCAC) 1996-1997 Member, Strategic Planning Committee for the Society for the Study of Reproduction 1996 Scientific Officer, Grants Panel of the National Cancer Institute of Canada 1996-1998 Coordinator, Registry of high school coop placement supervisors in Ottawa 1995-1996 Chair, Education Committee, Society for the Study of Reproduction 1995-1997 Member, CCAC Subcommittee on Guidelines for Transgenic Animal Use 1994-1995 Member, Education Committee, Society for the Study of Reproduction 1990-1998 Member, Board of Trustees, Mogenson Trust in Physiology, Univ. of Western Ontario

4

ADMINISTRATIVE ACTIVITIES (continued)

Internal 2014 Member, Search Committee for CRC-2 Chair in Pharmacology 2012-present Member, Departmental Tenure and Promotion Committee, Dept. of Cellular and Molecular Medicine 2012-2013 Member, Search Committee for Chair of Dept. of Obstetrics and Gynecology 2006-2013 Member, OHRI Scientific Appointment Review Committee 2010 Member, Roundtable on the Quality of the Student Experience (strategic planning) 2010 Member, Selection Committee, Echo’s Endowed Chair in Women’s Health Research 2006-present Member, Search Committee, Dept. of Cellular and Molecular Medicine 2006-present Director, Science Travels / La science voyage outreach program 2005-present Member, OHRI Training Committee 2004-2007 Member, Clinical Research Governing Council, The Ottawa Hospital 2004, 2011 Member, Selection Committee, Faculty of Medicine Award of Excellence 2003-2011 Member, Executive Committee, Faculty of Graduate and Postdoctoral Studies 2003-2011 Member, Academic Planning Committee, Faculty of Graduate and Postdoctoral Studies 2003-2011 Chair, Commission on Graduate Studies in the Sciences 2003 Member, Institutional Self-Study Sub-Committee on Graduate and Postdoctoral Studies 2003-2011 Member, Animal Care Committee Protocol Review Group 2002-2012 Member, Organizing Committee, The Ottawa Evening 2001-2003 Ottawa Academic Health Sciences Leadership Program Planning Committee 2001-2003 Member, Subcommittee on Compliance Issues, Animal Care Committee 2001-2002 Member, Search Committee for the Chair of the Department of Cellular and Molecular Medicine 1999-2001 Member, Summer Student Committee, Ottawa Health Research Institute 1995-2007 Member, Animal Care Committee, Faculty of Medicine, University of Ottawa 1995-2006 Coordinator, Ovarian Cancer Research Discussion Group, Ottawa Regional Cancer Centre 1995-1997 Member, Gender Issues Committee, Faculty of Medicine, University of Ottawa 1995, 1997 Moderator, Symposium on Gynecological Malignancies, Ottawa Reproductive Biology Workshop 1995 Member, Selection Committee, Dept. of Anatomy and Neurobiology, Univ. of Ottawa 1994-1999 Member, Graduate Studies Committee, Dept. of Cellular & Molecular Medicine, Univ. of Ottawa 1994 Master's Comprehensive Exam Committee, Dept. of Physiology, Univ. of Ottawa 1993-present Director, Let's Talk Science/Parlons Sciences Program 1993-2014 Coordinator, Work-in-Progress Sessions, Cancer Research Labs, ORCC 1993-2007 Director, Transgenic Mouse Facility, University of Ottawa 1993-1999 Member, Committee for the Bachelor of Medical Science Program 1992-2003 Member, Organizing Committee for Annual Ottawa Reproductive Biology Workshop 1986-1988 Member, Appointments Committee, Dept. of Physiology, U.W.O. 1986-1988 Member, Promotion & Tenure Committee, Dept. of Physiology, U.W.O. 1986-1987 President, Graduate Student Council, Dept. of Physiology, U.W.O. REVIEWER Journals (Ad hoc) American Journal of Obstetrics & Gynecology Biology of Reproduction BMC Cancer Canadian Journal of Physiology & Pharmacology Cancer Research Cell Growth and Differentiation Clinical Cancer Research Developmental Biology Developmental Genetics Differentiation Endocrinology European Journal of Cancer Experimental Cell Research

Gynecologic Oncology Human Reproduction International Journal of Cancer Journal of Clinical Endocrinology and Metabolism Journal of Endocrinology Journal of Ovarian Research Molecular Endocrinology Molecular Oncology Molecular Reproduction and Development PLoS One Reproduction Reproductive Biology and Endocrinology Science

5

REVIEWER (continued) Editorial Boards Biology of Reproduction (previous) BMC Cancer (current) Mol. Reprod. & Development (Assoc. Editor) (previous) Journal of Ovarian Research (current) Challenge - Life with Cancer (Chair) (previous)

Granting Agencies Alberta Heritage Foundation for Medical Research Medical Research Council (U.K.) Canadian Cancer Society Research Institute Michael Smith Foundation for Health Research Canadian Institutes of Health Research National Cancer Institute of Canada Cancer Research Society National Institutes of Health, U.S.A. European Commission’s Programme for Research National Science Foundation, U.S.A Fonds de la Recherche en Santé du Québec Natural Sciences and Engineering Res. Council of Canada The Israel Science Foundation United States-Israel Binational Science Foundation Meeting Abstracts Canadian Fertility and Andrology Society International Embryo Transfer Society Society for the Study of Reproduction

PROFESSIONAL MEMBERSHIPS Canadian Federation of Biological Sciences Canadian Physiological Society Canadian Fertility and Andrology Society Society for the Study of Reproduction

TEACHING EXPERIENCE 2010-12 Lecturer - Advanced topics in Developmental Biology, BIO 4314 /BIO 4109 2009-14 Course coordinator and lecturer - Community Outreach and Media Relations in the Sciences,

ESG 5310 (English) and ESG 5710 (French) 2006-14 Lecturer - Physiology and pathophysiology of the reproductive, renal and

gastrointestinal system, CMM 5313 2004-13 Course coordinator and lecturer - Advanced Topics in Reproductive Biology, CMM 8300 2004-13 Lecturer - Advanced Topics in Cancer Biology, CMM 8105 2004-13 Lecturer - Molecular Biology of Diseases, BCH 8103 2003-04 PBL Tutor - Development and Homeostasis Block 2002 Lecturer - Cell Growth and Developmental Biology, CMM 8104 2001, 2004 PBL Tutor - Human Sexuality and Reproduction Block 2000 Lecturer - Topics in Biotechnology, BCH 4172 2000-13 Lecturer - Developmental Biology, CMM 5304 2000 Lecturer - Biology of Reproduction, Anatomy 416, Queen’s University 1999-2011 Lecturer - Postgraduate Lecture, Department of Obstetrics and Gynecology 1999 Lecturer - Oncology Residents Program 1998-2004 Lecturer - Molecular Biology of Human Disease, BCH 8105 1998-99 Lecturer - Advanced Topics in Reproductive Biology PHS 8000 1993-2013 Lecturer - Mammalian Physiology PHS 3240/5210 1991-2013 Lecturer - Reproductive Physiology PHS 4336/5336 1985-88 Teaching Assistant - Physiology 020/130 - U.W.O. 1983-85 Laboratory Demonstrator - Biology 310 - U.W.O.

6

TRAINEES AND MENTORSHIP Post-doctoral Associates:

Paul Magarelli, M.D. 1995 visiting scientist, University of Michigan Eva Nagyova, Ph.D. 1997 postdoctoral fellow (funded by OECD) Adedayo Adeeko, Ph.D. 1997-99 postdoctoral fellow Ken Garson, Ph.D. 1999-present research associate Jean-François Ethier, Ph.D. 03/2002 -09/2006 postdoctoral fellow (funded by Senior Fellowship in Gyne

Cancer Research from Cancer Care Ontario/NOCA Fiona Thomas, Ph.D. 04/2003 - 09/2005 postdoctoral fellow (funded by Strategic Training

Initiative in Research in Reproductive Health Sciences Lesley Dunfield, Ph.D. 08/2003 - 03/2006 postdoctoral fellow (funded by NCIC) Desheng Yao, M.D. 08/2003 - 12/2004 visiting scientist (Guangxi Cancer Hospital, China) Tatsuhiko Shigeto, M.D. 04/2005 - 10/2005 visiting scientist (Hirosaki University, Japan) Jin-Yi Jiang 05/2007 - 08/2008 postdoctoral fellow Yong Tang, M.D. 04/2009 - 03/2010 visiting scientist (Guangxi Cancer Hospital, China) François Paradis 09/2009 - 12/2010 postdoctoral fellow (funded by a Lalor Fellowship)

Graduate Students:

Rubina Ismail Ph.D., 1991-1997 Angela Tonary Ph.D., 1994-2000 (funded by Cancer Research Society and OGS) Eniko Keszthelyi M.Sc., 1996-1998 (funded by Genesis Research Foundation & NSERC) Anil Dhawan M.Sc., 1997-1999 (funded by Division of Reproductive Medicine) Manon Prevost M.Sc., 1998-2002 (funded by OGSST and NSERC) Suzanne Papademetriou M.Sc., 1999-2001 (funded by OGSST) Tanya Shaw Ph.D., 1999-2005 (funded by OGSST, OGS and CIHR) Katherine Clark Ph.D., 2001-2007 (funded by OGSST and OGS) Lisa Vandermeer M.Sc., 2002-2004 Michael Steller M.Sc., 2002-2004 David Pépin Ph.D., 2003-2011 (funded by OGSST) Laura Laviolette Ph.D., 2004-2011 (funded by CIHR) Rita Shamoon M.Sc., 2004-2007 (funded by NSERC) Lisa Turchet Ph.D., 2006-2013 (funded by CIHR and a REDIH scholarship) Valerie Snoulten M.Sc., 2006-2008 (funded by OGSST) Behnam Azadi M.Sc., 2007-2011 Elizabeth Pitre M.Sc., 2007-2010 (funded by OGS and CIHR) Sara Rafferty M.Sc., 2009-2011 (funded by CIHR) Fujian Yan M.Sc., 2009-2011 (funded by PharmaGap) Kendra Hodgkinson Ph.D. candidate, 2009-present (funded by CIHR, OGS and CIHR-REDIH) Kholoud Al-Wosaibai Ph.D. candidate, 2010-present (funded by a Saudi Arabian government scholarship) Ensaf Alhujaily Ph.D. candidate, 2011-present (funded by a Saudi Arabian government scholarship) Nhung (Rose) Vuong Ph.D. candidate, 2011-present (funded by CIHR-REDIH and QEII-GSST) Lauren Carter Ph.D. candidate, 2012-present (funded by CIHR-REDIH) Curtis McCloskey Ph.D. candidate, 2012-present (funded by OGS) Pascale Charette-Robineau M.Sc. candidate, 2013-present

Honours and Coop Students: 19 Advisory Committees: 65 High School Coop Students: 11 Thesis Defence Examiner: 48 (17 as external examiner at other institutions)

Summer Students: 34

7

RESEARCH FUNDING (Vanderhyden is PI unless indicated otherwise.) 2014-2019 Canadian Institutes of Health Research, “Role of ovarian epithelial progenitor cells in ovulatory

wound repair”. Operating grant: $124,037/year.

2014-2016 Cancer Research Society, “Role of PAX2 in the etiology of ovarian and fallopian tube cancers”. Operating grant: $60,000/year

2013-2015 Cancer Research Society, “Ovulation-associated risks for ovarian cancer”. Operating grant: $60,000/year

2012-2014 Cancer Research Society, “Biological impact of the loss of Hoxa5 gene function on ovary homeostasis and tumorigenesis.” PI is Lucie Jeannotte. Operating grant: $60,000/year

2012-2014 University of Ottawa Faculty of Medicine Translational Research Grant, “FGL2 from the ovary to the baby”. Co-PI with Andrée Gruslin. Operating grant: $50,000/year

2011-2014 Canadian Cancer Society Research Institute, “Roles of BRCA1 and PAX2 in the initiation of ovarian cancer”. Operating grant: $138,473/year

2011-2012 Marsha Rivkin Foundation, “Role of PAX2 in the etiology of ovarian and fallopian tube cancers”. Pilot project: US$75,000

2011-2014 Canadian Institutes of Health Research, “Effects of reproductive factors on ovarian cancer initiation and progression”. Operating grant: $129,693/year

2011-2012 Canadian Institutes of Health Research, “Role of Sca1+ ovarian surface epithelial cells in ovulatory wound repair”. Operating grant: $100,000 (priority bridge funds)

2011 University of Ottawa SME4SME program, “Development of a novel cytotoxic therapeutic for the treatment of ovarian cancer”. Operating grant: $50,000 (uOttawa) + $25,000 (PharmaGap)

2010 Ottawa Regional Cancer Foundation. Pilot Project: Simultaneous treatment with JX-594 oncolytic virus and paclitaxel as a new treatment for ovarian cancer. $26,024

2010-2011 Ottawa Regional Cancer Foundation, “Ovarian cancer research program”. Operating grant: $50,000.

2010-2011 Terry Fox Research Institute, “Canadian Ovarian Experimental Unified Resource”. PI is Anne-Marie Mes-Masson; Vanderhyden's role: Member of the Management Committee and Director of one of the biobank resources. Amount allotted to Vanderhyden: $65,000

2009-2015 CIHR Strategic Training Initiative in Health Research grant, “CIHR Training Program in Reproduction, Early Development and the Impact on Health (REDIH)”. (Nominated PI is Dr. Jay Baltz; Dr. Vanderhyden is a PI). $164,558 in year 1 and $324,608 in each of years 2-6 (total $1,787,598)

2009-2011 PharmaGap, Inc., “Evaluation of the therapeutic efficacy of GAP-107B8 in ovarian cancer”. $117,867.

2009 Ovarian Cancer Canada, “Characterization of stem/progenitor cells in ovarian surface epithelium”. Pilot project grant: $30,000

2008 Ottawa Regional Cancer Foundation, funding for ovarian cancer research: $20,038.

2007-2010 Canadian Institutes of Health Research, “Effects of reproductive and genetic factors on ovarian cancer initiation and progression”. Operating grant: $133,541/year

2007-2010 Ontario Institute for Cancer Research, "Mouse models of ovarian cancer". Operating grant: $127,091/year.

8

RESEARCH FUNDING (continued) 2007 CIHR Meeting grant: Second Sino-Canada Bilateral Workshop on Reproductive health,

$5,000

2007 Ottawa Regional Cancer Foundation, funding for ovarian cancer research: $12,728.

2006-2008 Cancer Research Society, "VSV oncolytic virus therapy for ovarian cancer". Operating grant: $60,000/year

2006-2009 Canadian Institutes of Health Research, “Role of chromatin remodeling proteins in gonadal function”. Operating grant: $113,861/year

2005-2006 Ottawa Regional Cancer Centre Foundation, “VSV oncolytic virus as a treatment for ovarian cancer”. Pilot Project: $30,000.

2005 University of Ottawa, International Creative Research Award, “Testing of Novel Treatment Strategies for Ovarian Cancer”. $20,000

2004-2007 Canadian Institutes of Health Research, “Effects of reproductive and genetic factors on ovarian cancer initiation and progression”. Operating grant: $122,706/year

2003-2004 Arius Research Inc., “Efficacy evaluation of ARIUS antibodies in xenograft models of ovarian cancer”. Pilot Study: $11,954

2003-2004 Aegera Oncology Inc., “Evaluation of Aegera antisense oligonucleotides in xenograft models of ovarian cancer”. Pilot Study: $17,200

2003-2004 Gynecologic Oncology Group, “A Phase II evaluation of Gleevec in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma”. Translational Research Project: $33,900 U.S.

2003-2004 Ottawa Regional Cancer Centre Foundation, “Effects of reproductive and genetic factors on ovarian cancer initiation and progression”. Pilot Project: $17,000

2003-2006 National Cancer Institute of Canada, “Role of the c-kit protooncogene in ovarian tumorigenesis”. Operating grant: $150,000/year

2003-2007 Canadian Institutes of Health Research, “Program in Oocyte Health”. (PI is Dr. Jay Baltz; Dr. Vanderhyden is a Project Leader). Operating grant: $549,315/year

2001-2003 Cancer Research Society, “Defining the role of ISWI proteins in the pathogenesis of ovarian cancer” (PI is Dr. David Picketts). Operating grant: $60,000/year

2000-2003 National Cancer Institute of Canada, “Role of the c-kit protooncogene in ovarian tumorigenesis”. Operating grant: $111,303/year

2000-2003 Canadian Institutes of Health Research, “Role of the c-kit protooncogene in ovarian tumorigenesis”. Operating grant: $83,948/year (declined in favour of NCIC award)

1999-2004 National Cancer Institute, “Mouse models of ovarian cancer” (PI is Dr. Thomas Hamilton, Fox Chase Cancer Center): $482,146 (U.S.)/year

1999-2003 Premier’s Research Excellence Award: $150,000 total for support of trainees

1999-2002 National Ovarian Cancer Association, “Pilot Project: Canadian Ovarian Cancer Tissue Bank” (joint with Drs. Patricia Shaw and Nelly Auersperg): $132,719/year

1999 Adherex Technologies Inc., “Effect of cell adhesion blockers on the aggregation and survival of ovarian cancer cells”. Project contract: $57,000

9

RESEARCH FUNDING (continued) 1998-2001 Medical Research Council of Canada, “Extracellular and intracellular control of oocyte growth”.

Operating grant (PI is Dr. Hugh Clarke): $87,994/year

1998-2000 Cancer Research Society, “The oocyte: A model system to identify how cellular growth is initiated and maintained”. Operating grant: $45,000/year (declined after Oct. 1998)

1998 Charles River Canada, Animal Grant Program. Animals are being supplied at no charge for the project “Cell-cell communication in the ovary”. Value = $2,000.

1998 Ottawa Regional Cancer Centre Foundation, purchase of a freezer for the ovarian cancer tumour bank: $7,000

1997-1999 Ottawa Civic Hospital Foundation (through the Division of Reproductive Medicine, Dept. of Obstetrics & Gynecology), “Regulatory factors secreted by human embryos” - graduate student stipend for Anil Dhawan: $14,265/year

1997 Ottawa Regional Cancer Centre Foundation, “Investigation of soluble Kit as a diagnostic tool for ovarian cancer”. Operating funds: $20,000

1996-1999 Medical Research Council of Canada, “Role of the c-kit protooncogene in ovarian tumorigenesis”. Operating grant: $52,070/year

1996-1998 Cancer Research Society, “Role of the c-kit protooncogene in ovarian tumorigenesis”. Operating grant: $45,000/year (declined after October 1, 1996)

1996 Ottawa Regional Cancer Centre Foundation, “Development of an outreach program on cancer and cancer research”. $5,000

1995 Ontario Cancer Treatment and Research Foundation, Operating Funds: $80,000

1995 Kiwanis Club, purchase of a microtome: $7,000

1992-1995 Medical Research Council of Canada, "Function of the c-kit protooncogene receptor and its ligand in the ovary" ($57,978/year)

1991 University of Ottawa, Division of Medical Oncology, Equipment Grant: $20,000

1991 National Cancer Institute of Canada, Terry Fox Development Funds: $30,000

10

Funding for Outreach and Educational Activities Communications Course 2008-2011 University of Ottawa Development of Initiatives on the Quality of Learning and the

Student Experience for the project "Interdisciplinary Initiative for the Graduate Students' Education in Community Outreach and Media Relations", $22,614.

Science Travels Program 2013-2015 NSERC PromoScience grant for “Science Travels”: $45,000 per year

2011-2014 CIHR Synapse grant for “Science Travels: Northern Outreach” (science outreach project): $30,000 per year

2010-2012 NSERC PromoScience grant for “Science Travels”: $38,300 per year

2009-2015 Student Academic Success Service, University of Ottawa, subcontract of funds from the Ministry of Education and Training for Colleges and Universities for their aboriginal program, $20,000 per year (2009-2012) and $18,000 per year (2013-2015)

2006-2009 Government of Ontario, Ministry of Research and Innovation, "Science Travels", $50,000 per year

Let’s Talk Science Program 2009-2014 Ontario Research Fund (PI is Dr. Michael McBurney), Youth Outreach component of

ORF grant: $10,000 per year

2008-2013 University of Ottawa Administration Committee, $20,000 per year for half-time salary of LTS Program Manager

2008 University of Ottawa Faculty of Medicine, LTS operating funds: $5,000

2005-present University of Ottawa Faculty of Graduate and Postdoctoral Studies, two research assistantships ($9,526 per year) for LTS coordinators.

2001-present University of Ottawa Faculty of Science, LTS operating funds: $5,000 per year

11

PUBLICATIONS (Peer-reviewed) 1. Vanderhyden BC, A Rouleau and DT Armstrong (1986). Effect of removal of the ovarian bursa of the rat on

infundibular retrieval and subsequent development of ovulated oocytes. J. Reprod. Fert. 77: 393-399.

2. Vanderhyden BC, A Rouleau, EA Walton and DT Armstrong (1986). Increased mortality during early embryonic development after in-vitro fertilization of rat oocytes. J. Reprod. Fert. 77: 401-409.

3. Vanderhyden BC and DT Armstrong (1988). Decreased embryonic survival of in-vitro fertilized oocytes is due to retardation of pre-implantation development. J. Reprod. Fert. 83: 851-857.

4. Vanderhyden BC and DT Armstrong (1989). Role of cumulus cells and serum on in vitro maturation, fertilization and subsequent development of rat oocytes. Biol. Reprod. 40: 720-728.

5. Vanderhyden BC, KJ McLaughlin, JM Rutledge and DT Armstrong (1989). Zona drilling increases the penetrability of rat oocytes matured in vitro. Biol. Reprod. 40: 953-960.

6. Vanderhyden BC and DT Armstrong (1990). Effects of gonadotropins and granulosa cell secretions on the maturation and fertilization of rat oocytes in vitro. Mol. Reprod. Devel. 26: 337-346.

7. Buccione R, BC Vanderhyden, PJ Caron and JJ Eppig (1990). FSH-induced expansion of the mouse cumulus oophorus in vitro is dependent upon a specific factor(s) secreted by the oocyte. Dev. Biol. 138: 16-25.

8. Vanderhyden BC, PJ Caron, R Buccione and JJ Eppig (1990). Developmental pattern of the secretion of cumulus expansion-enabling factor by mouse oocytes and the role of oocytes in promoting granulosa cell differentiation. Dev. Biol. 140: 307-317.

9. Armstrong DT, X Zhang, BC Vanderhyden and F Khamsi (1991). Hormonal actions during oocyte maturation that influence fertilization and early embryonic development. Ann. N.Y. Acad. Sci. 626: 137-158.

10. Vanderhyden BC, EE Telfer and JJ Eppig (1992). Mouse oocytes promote proliferation of granulosa cells from preantral and antral follicles in vitro. Biol. Reprod. 46: 1196-1204.

11. Morley P, JF Whitfield, BC Vanderhyden, BK Tsang and J-L Schwartz (1992). A new, non-genomic estrogen action: The rapid release of intracellular calcium. Endocrinology 131: 1305-1312.

12. Vanderhyden BC (1993). Species differences in the regulation of cumulus expansion by an oocyte-secreted factor(s). J. Reprod. Fert. 98: 219-227.

13. Vanderhyden BC, JN Cohen and P Morley (1993). Mouse oocytes regulate granulosa cell steroidogenesis. Endocrinology 133: 423-426.

14. Morley P, J Wang, BC Vanderhyden, B Chakravarthy, J Durkin and JF Whitfield (1993). The effect of cholecystokinin on intracellular Ca2+, membrane-associated protein kinase-C activity, and progesterone production in chicken granulosa cells. Endocrinology 133: 1956-1962.

15. Morley P, BC Vanderhyden, R Tremblay, GAR Mealing, JP Durkin and JF Whitfield (1994). Purinergic receptor-mediated intracellular Ca2+ oscillations in chicken granulosa cells. Endocrinology 134: 1269-1276.

16. Vanderhyden BC and AM Tonary (1995). Differential regulation of progesterone and estradiol production by mouse cumulus and mural granulosa cells by a factor(s) secreted by the oocyte. Biol. Reprod. 53: 1243-1250.

17. Ismail R, Y Okawara, JN Fryer and BC Vanderhyden (1996). Hormonal regulation of the ligand for the c-kit protooncogene in the ovary and its effects on spontaneous oocyte meiotic maturation. Mol. Reprod. Dev. 43: 458-469.

18. Seifer DB, MR Freeman, AC Gardiner, GA Hill, AL Schneyer and BC Vanderhyden (1996). Autologous granulosa cell co-culture demonstrates zygote suppression of granulosa cell steroidogenesis. Fert. Steril. 66: 425-429.

19. Vanderhyden BC (1996). Oocyte-secreted factors regulate granulosa cell steroidogenesis. Zygote 4: 317-321.

20. Costa SL, K Boekelheide, BC Vanderhyden, R Seth and MW McBurney (1997). Male infertility caused by epididymis dysfunction in transgenic mice expressing a dominant negative mutation of RARα. Biol. Reprod. 56: 985-990.

12

21. Ismail RS, M Dubé and BC Vanderhyden (1997). Hormonally-regulated alternative splicing of Kit ligand may regulate Kit-induced inhibition of meiosis in rat oocytes. Dev. Biol. 184: 333-342.

22. Di Fruscio M, W Weiher, BC Vanderhyden, T-A Hori, T Shiomi, T Imai, R Jaenisch and DA Gray (1997). Mpv 20: Proviral inactivation of the Npat gene results in early embryonic arrest. Mol. Cell. Biol. 17: 4080-4086.

23. Vanderhyden BC, EA Macdonald, H Merchant-Larios, A Fernandez, A Amleh, R Nasseri and T Taketo (1997). Interactions between the oocyte and cumulus cells in the ovary of the B6.YTIR sex-reversed female mouse. Biol. Reprod. 57: 641-646.

24. Vanderhyden BC and EA Macdonald (1998). Mouse oocytes regulate granulosa cell steroidogenesis throughout follicular development. Biol. Reprod. 59: 1296-1301.

25. Abraham N, DF Stojdl, PI Duncan, N Méthot, T Ishii, M Dubé, BC Vanderhyden, HL Atkins, DA Gray, MW McBurney, AE Koromilas, EG Brown, N Sonenberg and JC Bell (1999). Characterization of transgenic mice with targeted disruption of the catalytic domain of the double-stranded RNA-dependent protein kinase, PKR. J. Biol. Chem. 274: 5953-5962.

26. Ismail RS, M Cada and BC Vanderhyden (1999). Transforming growth factor-β regulates Kit ligand expression in rat ovarian surface epithelial cells. Oncogene 18: 4734-4741.

27. Nagyova E, Procházka R and BC Vanderhyden (1999). Oocytectomy does not influence synthesis of HA by pig cumulus cells: Retention of HA after IGF-I treatment in serum-free medium. Biol. Reprod. 61: 569-574.

28. Dhawan A, MC Leveillé and BC Vanderhyden (2000). Human embryos suppress granulosa cell steroidogenesis: Relationship to embryo quality and developmental competence. Human Reprod. 15: 917-924.

29. Tonary AM, EA Macdonald, W Faught, M Senterman and BC Vanderhyden (2000). Lack of expression of c-kit in ovarian cancers is associated with poor prognosis. Int. J. Cancer 89: 242-250.

30. Nagyova E, BC Vanderhyden and R Procházka (2000). Secretion of paracrine factors enabling expansion of cumulus cells is developmentally regulated in pig oocytes. Biol. Reprod. 63: 1149-1156.

31. Li J, Q Feng, J-M Kim, D Schneiderman, P Liston, M Li, B Vanderhyden, W Faught, M Fung Kee Fung, M Senterman, RG Korneluk and BK Tsang (2001). Human ovarian cancer and cisplatin resistance: Possible role of inhibitor of apoptosis proteins. Endocrinology 142: 370-380.

32. Tsirigotis M, S Thurig, M Dubé, BC Vanderhyden, M Zhang and DA Gray (2001). Analysis of ubiquitination in vivo using a transgenic mouse model. BioTechniques 31: 120-130.

33. Shaw TJ, EJ Keszthelyi, AM Tonary, M Cada and BC Vanderhyden (2002). Cyclic AMP in ovarian cancer cells both inhibits proliferation and increases c-kit expression. Exp. Cell Res. 273: 95-106.

34. Connolly DC, R Bao, AY Nikitin, KC Stephens, TW Poole, X Hua, SS Harris, BC Vanderhyden and TC Hamilton (2003). Female mice chimeric for the expression of the SV40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Research 63: 1389-1397.

35. Garson K, EA Macdonald, M Dubé, R. Bao, TC Hamilton and BC Vanderhyden (2003). Generation of tumors in transgenic mice expressing the SV40 T antigen under control of OSP-1 (Ovarian Specific Promoter 1). J. Soc. Gyn. Invest. 10: 244-250.

36. Michaud, J-L, LI Lemieux, M Dubé, BC Vanderhyden, SJ Robertson and CRJ Kennedy (2003). Focal and segmental glomerulosclerosis in mice with podocyte-specific overexpression of mutant α-actinin-4. J. Am. Soc. Nephrol. 14: 1200-1211. Also appearing in “This Month’s Highlights” of the same issue.

37. Vanderhyden BC, EA Macdonald, E Nagyova and A Dhawan (2003). Evaluation of members of the TGFβ superfamily as candidates for the oocyte factors that control cumulus expansion and steroidogenesis. Reproduction, Supplement 61: 55-70.

38. Hamilton TC, DC Connolly, AY Nikitin, K Garson and BC Vanderhyden (2003). Translational research in ovarian cancer: A must. Int. J. Gynecol. Cancer 13 (Suppl. 2): 220-230.

39. Shaw TJ, MK Senterman, K Dawson, CA Crane and BC Vanderhyden (2004). Characterization of intra-peritoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol. Therapy 10: 1032-

13

1042.

40. Thomas FH, J-F Ethier, S Shimasaki and BC Vanderhyden (2005). Follicle-stimulating hormone regulates oocyte growth by modulation of expression of oocyte and granulosa cell factors. Endocrinology 146: 941-949.

41. Gittens JEI, KJ Barr, BC Vanderhyden and GM Kidder (2005). Interplay between paracrine signalling and gap junctional communication in ovarian follicles. J. Cell Sci. 118: 113-122.

42. Gilks CB, BC Vanderhyden, S Zhu, M van de Rijn, TA Longacre (2005). Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol. Oncol. 96: 684-694.

43. Steller M, TJ Shaw, BC Vanderhyden and J-F Ethier (2005). Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells. Mol. Cancer Res. 3: 50-61.

44. Chambers AF and BC Vanderhyden (2006). Ovarian cancer biomarkers in urine. (Commentary). Clinical Cancer Research 12: 323-327.

45. Lazzaro MA, D Pépin, N Pescador, BD Murphy, BC Vanderhyden and DJ Picketts (2006). The ISWI protein SNF2L regulates steroidogenic acute regulatory protein (StAR) expression during terminal differentiation of ovarian granulosa cells. Mol. Endocrinol. 20: 2406-2417.

46. Clark-Knowles KV, K Garson, J Jonkers and BC Vanderhyden (2007). Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. Exp. Cell Res. 313: 133-145.

47. Shaw TJ and BC Vanderhyden (2007). AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate. Gynecol Oncol. 105:122–131.

48. Thomas FH, RS Ismail J-Y Jiang and BC Vanderhyden (2008). Kit ligand 2 promotes murine oocyte growth in vitro. Biol. Reprod. 78: 167-175.

49. Shaw TJ, EC Lacasse, JP Durkin and BC Vanderhyden (2008). Down-regulation of XIAP expression in ovarian cancer cells induces apoptosis in vitro and in vivo. Int. J. Cancer 122: 1430-1434.

50. Schilder RJ, MW Sill, RB Lee, TJ Shaw, MK Senterman, AJP Klein-Szanto, Z Miner and BC Vanderhyden (2008). A Phase II evaluation of imatinib methylate in the treatment of recurrent or persistent ovarian or primary peritoneal carcinoma. J. Clin. Onc. 26: 3418-3425.

51. Nguyên TL-A, H Abdelbary, M Arguello, C Breitbach, S Leveille, J-S Diallo, A Yasmeen, TA Bismar, D Kirn, T Falls, VE Snoulten, BC Vanderhyden, J Werier, H Atkins, MJV Vähä-Koskela, DF Stojdl, JC Bell and J Hiscott (2008). Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc. Nat. Acad. Sci. 105: 14981-14986.

52. Shah SP, Köbel M, Senz J, Morin RD, Clarke BA, Wiegand KC, Leung G, Zayed A, Mehl E, Kalloger SE, Sun M, Giuliany R, Yorida E, Jones S, Varhol R, Swenerton KD, Miller D, Clement PB, Crane C, Madore J, Provencher D, Leung P, DeFazio A, Khattra J, Turashvili G, Zhao Y, Zeng T, Glover JN, Vanderhyden B, Zhao C, Parkinson CA, Jimenez-Linan M, Bowtell DD, Mes-Masson AM, Brenton JD, Aparicio SA, Boyd N, Hirst M, Gilks CB, Marra M, Huntsman DG. (2009). Mutation of FOXL2 in granulosa-cell tumors of the ovary. N. Engl. J. Med. 360: 2719-2729.

53. Clark-Knowles KV, MK Senterman, O Collins and BC Vanderhyden (2009). Conditional inactivation of Brca1, p53, and Rb in mouse ovaries results in the development of leiomyosarcomas. PLoS ONE 4(12):e8534.

54. Laviolette LA, K Garson, EA Macdonald, MK Senterman, K Courville, CA Crane and BC Vanderhyden. (2010). 17β-estradiol accelerates tumor onset and decreases survival in a transgenic mouse model of ovarian cancer. Endocrinology 151: 929-938.

55. Stitt-Cavanagh EM, WH Faour, K Takami, A Carter, B Vanderhyden, Y Guan, A Schneider, MD Breyer, CR Kennedy (2010). A maladaptive role for EP4 receptors in podocytes. J. Am. Soc. Nephrol. 21: 1678-1690.

56. Laviolette LA, J-F Ethier, MK Senterman, PJ Devine and BC Vanderhyden (2011). Induction of a menopausal state alters the growth and histology of ovarian tumors in a mouse model of ovarian cancer. Menopause 18: 549-557.

14

57. Pépin D, ZQ Shao, G Huppé, A Wakefield, CW Chu, Z Sharif and BC Vanderhyden (2011). Kallikreins 5, 6 and 10 differentially alter pathophysiology and overall survival in an ovarian cancer xenograft model. PLoS One. 6(11): e26075.

58. Parato K, CJ Breitbach, F Le Boeuf, J Wang, C Storbeck, C Ilkow, JS Diallo, T Falls, J Burns, V Garcia, F Kanji, L Evgin, K Hu, F Paradis, S Knowles, TH Hwang, BC Vanderhyden, R. Auer, DH Kirn and JC Bell (2012). The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol. Ther. 20: 749-758.

59. Gamwell LF, O Collins and BC Vanderhyden (2012). The mouse ovarian surface epithelium contains a population of LY6A (SCA-1) expressing progenitor cells that are regulated by ovulation-associated factors. Biol. Reprod. 87: 80.

60. Garson K, Gamwell LF, E Pitre and BC Vanderhyden (2012). Technical challenges and limitations of current mouse models of ovarian cancer. J. Ovarian Res. 5: 39.

61. Lemay CG, JL Rintoul, A Kus, JM Paterson, V Garcia, TJ Falls, L Ferreira, BW Bridle, DP Conrad, VA Tang, JS Diallo, R Arulanandam, F Le Boeuf, K Garson, BC Vanderhyden, DF Stojdl, BD Lichty, HL Atkins, KA Parato, JC Bell and RC Auer (2012). Harnessing oncolytic virus-mediated anti-tumour immunity in an infected cell vaccine. Mol. Ther. 20: 1791-1799.

62. King SM, SM Quartuccio SM, BC Vanderhyden and JE Burdette (2013). Early transformative changes in normal ovarian surface epithelium induced by oxidative stress require Akt upregulation, DNA damage, and epithelial-stromal interaction. Carcinogenesis 34: 1125-1133.

63. Gamwell LF, M Merziotis, K Gambaro, SL Arcand, V Snoulten, C Davis, JA Squire, DL Huntsman, PN Tonin and BC Vanderhyden (2013). Characterization of a small cell ovarian cancer cell line: Genomic anomalies and responsiveness to therapeutics. Orphanet Journal of Rare Diseases 8: 33.

64. Le Page C, Köbel M, de Ladurantaye M, Rahimi K, Madore J, Babinszky S, Bachvarov DR, Bachvarova M, Beauchamp MC, Cass CE, Chadwick D, Colleen C, Damaraju S, Dufour J, Gotlieb WH, Kalloger SE, Portelance L, McAlpine JN, Matte I, Piché A, Shaw P, Roehrl MH, Vanderhyden BC, Watson PH, Huntsman DG, Provencher DM, Mes-Masson AM (2013). Specimen quality evaluation in Canadian biobanks participating in the COEUR repository. Biopreserv. Biobank. 11: 83-93.

65. Pépin D, Paradis F, Perez-Iratxeta C, Picketts DJ, Vanderhyden BC (2013). The imitation switch ATPase Snf2l is required for superovulation and regulates Fgl2 in differentiating mouse granulosa cells. Biol. Reprod.. 88: 142. doi: 10.1095/biolreprod.112.105742.

66. Wardell JR, KM Hodgkinson, AK Binder, KA Seymour, KS Korach, BC Vanderhyden and RN Freiman (2013). Estrogen responsiveness of the TFIID subunit TAF4B in the normal mouse ovary and in ovarian tumors. Biol. Reprod. 89: 116. doi: 10.1095/biolreprod.113.111336

67. Abdallah BY, SD Horne, JB Stevens, G Liu, AY Ying, BC Vanderhyden, SA Krawetz, R Gorelick, HHQ Heng (2013). Single cell heterogeneity: why unstable genomes are incompatible with average profiles. Cell Cycle 12: 3640-3649

68. Vulesevic B, B McNeill, M Geoffrion, D Kuraitis, JE McBane, M Lochhead, BC Vanderhyden, GS Korbutt, RW Milne, and EJ Suuronen (2014). Glyoxalase-1 over-expression in bone marrow cells reverses defective neovascularization in streptozotocin-induced diabetic mice. Cardiovasc. Res. 101: 306-316.

69. Laviolette LA, Hodgkinson KM, Minhas N, Perez-Iratxeta C, Vanderhyden BC (2014). 17β-estradiol upregulates GREB1 and accelerates ovarian tumour progression in vivo. Int. J. Cancer. Jan 27. doi: 10.1002/ijc.28741.

70. McCloskey CW, Goldberg RL, Carter LE, Gamwell LF, Al-Hujaily EM, Collins O, Macdonald EA, Garson K, Daneshmand M, Carmona E and Vanderhyden BC (2014). Characterization of a stem cell-like population in a spontaneously transformed syngeneic model of high-grade serous ovarian cancer. Front Oncol. 4: 53.

71. Ribeiro JR, LA Lovasco, BC Vanderhyden and RN Freiman (2014). Targeting TBP-associated factors in ovarian cancer Front Oncol. 4: 45.

72. Geoffrion M, Du X, Irshad Z, Vanderhyden BC, Courville K, Sui G, D'Agati VD, Ott-Braschi S, Rabbani N,

15

Thornalley PJ, Brownlee M, Milne RW (2014). Differential effects of glyoxalase 1 overexpression on diabetic atherosclerosis and renal dysfunction in streptozotocin-treated, apolipoprotein E-deficient mice. Physiol. Rep. 2. pii: e12043.

73. Ahmed YA, JY Kim, JF Pelletier, BC Vanderhyden, DR Bachvarov, BK Tsang (2014). Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability. (Mol. Carcinogenesis, in press).

74. Arulanandam R, C Batenchuk, O Varette, C Zakaria, NE Forbes, C Davis, R Krishnan, V Garcia, R Karmacharya, J Cox, A Sinha, A Babawy, K Waite, E Weinstein, T Falls, A Chen, J Hamill, N Da Silva, DP Conrad, H Atkins, K Garson, C Ilkow, M Kaern, B Vanderhyden, N Sonenberg, T Alain, F Le Boeuf , JC Bell and JS Diallo (2014). Microtubule destabilizers disrupt interferon production and sensitize to rhabdovirus bystander killing. (submitted to Nature).

MANUSCRIPTS IN PREPARATION 75. Papademetriou SA, CJ-Y Jiang, C Barchechat, M Kozlowski and BC Vanderhyden. Lack of PTPN6 expression

in mice inhibits follicular development and is associated with increased oocyte size.

76. Snoulten V, EA Macdonald and BC Vanderhyden. Therapeutic efficacy of vesicular stomatitis virus as a single agent or in combination with the histone deacetylase inhibitor, MS-275, in a mouse model of ovarian cancer.

77. Shamoon R, J-Y Jiang and BC Vanderhyden. Regulation of Kit Ligand expression in rat granulosa cells by extra- and intra-ovarian factors.

78. Gamwell LF, C McCloskey, O Collins and BC Vanderhyden. BRCA1 regulates a subpopulation of ovarian surface epithelial cells with stem/progenitor cell characteristics.

BOOK CHAPTERS AND REVIEW ARTICLES 1. Vanderhyden BC. (2002). Oocyte-granulosa cell interactions. In: Cell-cell interactions: A Practical

Approach. TP Fleming (Ed.). Oxford University Press. pp.177-201.

2. Vanderhyden BC (2002). Molecular basis of ovarian development and function. Frontiers in Bioscience 7: 2006-2022.

3. Vanderhyden BC, TJ Shaw and JF Ethier (2003). Animal Models of Ovarian Cancer. Reprod. Biol. and Endocrinology, 1: 67-77.

4. Vanderhyden BC, TJ Shaw, K Garson and AM Tonary. (2004). Ovarian Carcinogenesis. In: The Ovary, 2nd Edition. PCK Leung and EY Adashi (Eds.), Elsevier Academic Press, San Diego, California, pp 591-612.

5. Vanderhyden BC (2005). Loss of ovarian function and the risk of ovarian cancer. Cell and Tissue Research. 322: 117-124.

6. Garson K, TJ Shaw, KV Clark, DS Yao and BC Vanderhyden (2005). Models of ovarian cancer—Are we there yet? Mol. Cell. Endocrinol. 239: 15-26.

7. Thomas FH and BC Vanderhyden (2006). Oocyte-granulosa cell interactions during mouse follicular development: regulation of Kit ligand expression and its role in oocyte growth. Reprod. Biol. and Endocrinology, Apr 12; 4: 19.

8. Thomas FH and BC Vanderhyden (2007). Oocyte growth and developmental competence. In: In-vitro Maturation of Human Oocytes: From Basic Science to Clinical Application. SL Tan, RC Chiang and WM Buckett (Eds.). Informa Healthcare, Abingdon, UK, pp 1-14.

9. Pépin D, BC Vanderhyden, DJ Picketts and BD Murphy (2007). ISWI chromatin Remodeling in Ovarian Somatic and Germ Cells: Revenge of the NURFs. Trends Endocrinol. Metab. 18: 215-224.

10. Salehi F, LD Dunfield, KP Phillips, D Krewski and BC Vanderhyden (2008). Risk factors for ovarian cancer: An overview with emphasis on hormonal factors. J.Toxicol. Environ. Health, Part B, 11: 301-321.

11. Weberpals JI, KV Clark-Knowles and BC Vanderhyden (2008). Sporadic epithelial ovarian cancer: Clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway. J Clin. Oncol. 26: 3259-3267.

16

12. Vanderhyden BC and AM Dorward (2010). Ovarian Cancer and the Environment: Rodent Models. In: Comprehensive Toxicology, Charlene A McQueen (Ed), Academic Press, Oxford, UK. Volume 11: Female Reproductive Toxicology, pp. 483-498.

13. Kidder GM and BC Vanderhyden (2010). Bidirectional communication between oocytes and follicle cells: ensuring oocyte developmental competence. Can. J. Physiol. Pharmacol. 88: 399-413.

14. Hodgkinson K and BC Vanderhyden (2013). Endocrine effects on ovarian cancer: Insight from animal models. In: Ovarian Toxicology, 2nd Edition. PB Hoyer (Ed.), Taylor and Francis. pp.261-283.

15. Hodgkinson K and BC Vanderhyden (2014). Consideration of GREB1 as a potential therapeutic target for hormone-responsive and endocrine-resistant cancers. Expert Opinion On Therapeutic Targets, Jul 5:1-12.

16. Garson K and BC Vanderhyden (2014). Epithelial ovarian cancer stem cells: Underlying complexity of a simple paradigm. Reproduction (invited review, in revision)

PUBLICATIONS (non-peer-reviewed) Vanderhyden BC (1997). On the Frontier. In: Challenge - Life with Cancer. Spring/Summer issue, published by the Ottawa Regional Cancer Centre Foundation. (Subject: What is cancer?)

Vanderhyden BC (1997). On the Frontier. In: Challenge - Life with Cancer. Fall/Winter issue, published by the Ottawa Regional Cancer Centre Foundation. (Subject: Ovarian cancer)

McBurney M and Vanderhyden BC (1998). The Discoverers: charting the unexplored in the search for a cure. In: Challenge - Life with Cancer. Spring/Summer issue, published by the Ottawa Regional Cancer Centre Foundation.

Bailey DH, DC Connolly, BC Vanderhyden, K Garson and TC Hamilton (2002). Ovarian Cancer Models. Published on the Mouse Models of Human Cancers Consortium website at http://emice.nci.nih.gov/mouse_models/organ_models/ovarian_models.

Vanderhyden BC (2012). Ovarian Cancer Screening. In: MediaPlanet, a supplement to the National Post, September 2012. PUBLISHED ABSTRACTS 1. Vanderhyden B, A Rouleau-Coulter, EA Walton and DT Armstrong (1984). Increased embryonic mortality

following in vitro fertilization of rat oocytes. Biol. Reprod. 30 (Suppl. 1): p.45.

2. Kiehm DJ, A Rouleau, B Vanderhyden and DT Armstrong (1987). In vitro fertilization of rat oocytes following cryopreservation. Theriogenology 27(1): p.242.

3. Vanderhyden BC (1987). Increased embryonic survival of in vitro fertilized oocytes given additional time for pre-implantation development. Biol. Reprod. 36 (Suppl. 1): p.78.

4. Vanderhyden BC, KJ McLaughlin and DT Armstrong (1988). Zona drilling improves fertilization of in vitro matured rat oocytes. Biol. Reprod. 38 (Suppl. 1): p.71.

5. Vanderhyden BC, R Buccione and JJ Eppig (1989). FSH-induced cumulus expansion in vitro is dependent upon a factor secreted by the oocyte. In: "Fertilization in mammals". (B.D. Bavister, J. Cummins and E.R.S. Roldan, Eds.) pp. 422. Serono Symposia, USA, Norwell Massachusetts.

6. Vanderhyden BC, PJ Caron and JJ Eppig (1990). The role of the oocyte in promoting granulosa cell differentiation and proliferation. Biol. Reprod. 42 (Suppl. 1): p.174.

7. Vanderhyden BC, EE Telfer and JJ Eppig (1991). Murine oocytes modulate granulosa cell proliferation in preantral and antral follicles. Biol. Reprod. 44 (Suppl. 1): p.153.

8. Telfer EE, BC Vanderhyden and JJ Eppig (1991). Proliferation of the murine follicular epithelium is influenced by the oocyte. Eric K. Fernstrom Symposium, Lund, Sweden: Local regulation of ovarian function.

9. Ismail RS and BC Vanderhyden (1992). Localization of the ligand for the c-kit protooncogene in rat ovaries. Biol. Reprod. 46 (Suppl. 1): p.176.

10. Vanderhyden BC (1992). Species differences in the regulation of cumulus expansion by an oocyte-secreted factor(s). Biol. Reprod. 46 (Suppl. 1): p.138.

17

11. Morley P, J Wang, BC Vanderhyden, B Chakravarthy, J Durkin and JF Whitfield (1993). Cholecystokinin increases chicken granulosa cell [Ca2+]i and PKC activity, but does not affect progesterone production. Biol. Reprod. 48 (Suppl. 1): p.136.

12. Vanderhyden BC (1993). Mouse oocytes regulate granulosa cell steroidogenesis. Biol. Reprod. 48 (Suppl. 1): p.92.

13. Ismail RS and BC Vanderhyden (1994). Expression of kit ligand, the ligand for the c-kit receptor, in the female rat reproductive tract. Biol. Reprod. 50 (Suppl. 1): p.159.

14. Vanderhyden BC (1994). The role of oocytes in the inhibition of progesterone production. Biol. Reprod. 50 (Suppl. 1): p.187.

15. Vanderhyden BC and S Davoudi (1995). Oocyte-secreted factors regulate steroidogenic enzyme activities in rat cumulus granulosa cells. Biol. Reprod. 52 (Suppl. 1): p.126.

16. Tonary AM, RS Ismail, EA Macdonald, W Faught, M Senterman and BC Vanderhyden (1996). Expression of the c-kit protooncogene and its ligand in normal and immortalized ovarian surface epithelial cells and in ovarian cancer. Biol. Reprod. 54 (Suppl. 1): p.142.

17. Ismail RS, M Dubé and BC Vanderhyden (1996). Activation of the c-kit receptor prevents G2 to M transition in rat oocytes. Biol. Reprod. 54 (Suppl. 1): p. 186.

18. Ismail RS, EA Macdonald and BC Vanderhyden (1997). Characterization of rat ovarian surface epithelium: hormonal effects on proliferation, steroidogenesis and expression of Kit receptor and its ligand. Biol. Reprod. 56 (Suppl. 1): p. 128.

19. Vanderhyden BC, N MacDonald and BC Schmidt (1999). The Let’s Talk Science Partnership Program brings science to life. Biol. Reprod. 60 (Suppl. 1): p. 92.

20. Nagyová E, Procházka, R and BC Vanderhyden (2000). ffect of porcine oocytes at different stages of development on synthesis of hyaluronic acid by mouse oocytectomized complexes. Theriogenology 53: p. 462.

21. Gittens JEI, KJ Barr, BC Vanderhyden and GM Kidder (2000). Interactions between paracrine and gap junctional signalling pathways in the mouse ovary. Biol. Reprod. (Suppl. 1): p. 122.

22. Papademetriou SA, M Kozlowski and BC Vanderhyden (2001). The effects of SHP-1 deficiency on mouse ovarian follicle development. Biol. Reprod. (Suppl. 1): p. 37.

23. Wilson-Rawls J, J Johnson, SA Papademetriou and B Vanderhyden (2001). Jagged gene expression is altered in GDF-9 null and motheaten mice. Biol. Reprod. (Suppl. 1): p. 49.

24. Vanderhyden BC, E. Nagyova and A Dhawan (2001). Effects of TGF-β and GDF-9 on cumulus expansion and progesterone production by oocytectomized oocyte-cumulus cell complexes (2001). Biol. Reprod. (Suppl. 1): p. 51.

25. Shaw TJ, EJ Keszthelyi, AM Tonary, M Cada and BC Vanderhyden (2001). Cyclic AMP in ovarian cancer cells both inhibits proliferation and increases c-Kit expression. Biol. Reprod. (Suppl. 1): p. 61.

26. Garson K, M Dubé, DC Connolly, TC Hamilton and BC Vanderhyden (2001). The OSP-1 promoter directs expression of LacZ to the ovaries of transgenic mice. Biol. Reprod. (Suppl. 1): p.62.

27. Gilks B, B Vanderhyden, S Zhu, M van de Rijn and T Longacre (2003). Distinction between serous borderline tumors and serous carcinomas based on mRNA expression profiling. Mod. Pathol. 16:190A.

28. Connolly, D.C., Bao, R., Nikitin, A.Y., Leaner, V.D., Birrer, M.J., Hodgson, G.J., Gray, J.W., Stephens, K.C., Poole, T.W., Hua, X., Harris, S.S., Vanderhyden, B.C., and Hamilton, T.C. (2003). Molecular analyses of a transgenic mouse model of human epithelial ovarian cancer. Proc. Natl. Acad. Sci. USA.

29. Lacasse E, D McManus, G Cherton-Horvat, H Wang, E Kandimalla, R Zhang, S Agrawal, G Batist, M Kandouz, B Vanderhyden, T Shaw and Jon Durkin (2004). The XIAP antisense compound AEG35156/GEM640 demonstrates significant antitumour activity in multiple human cancer xenograft models. Proceedings of the AACR, Volume 45: 681, March 2004. (Abstract Number: 2947)

30. Pan Z-Z, B Vanderhyden and AK Godwin (2004). -Synuclein transgenic mouse model in tumorigenesis.

18

Proceedings of the AACR, Volume 45: 1178, Mar 2004 (Abstract Number: 5108).

31. Vandermeer L, AM Tonary and BC Vanderhyden (2004). Effect of extracellular matrix components on ovarian surface epithelial cells. Biol. Reprod., Special Issue, page 140.

32. Thomas FH, JF Ethier and BC Vanderhyden (2004). FSH regulates oocyte growth by modulation of expression of oocyte and granulosa cell factors. Biol. Reprod., Special Issue, page 223.

33. Thomas FH and BC Vanderhyden (2005). KL-2 is the principal KL isoform regulating murine oocyte growth and maintenance of meiotic arrest in vitro. Biol. Reprod. Special Issue, page 98.

34. Ethier, Jean-Francois, FH Thomas and BC Vanderhyden (2005). Initiation of oocyte growth in Growth and Differentiation Factor-9 (GDF9) deficient mice precedes both initiation of follicle development and the increase in Kit Ligand (KL) mRNA expression. Biol. Reprod. Special Issue, page 174.

35. Pépin, D, MA Lazzaro, N Pescador, BD Murphy, DJ Picketts and BC Vanderhyden (2005). The ISWI protein Snf2l regulates the initiation of transcription of the Steroidogenic Acute Regulatory protein (StAR) in terminally differentiating granulosa and Leydig cells. Biol. Reprod. Special Issue, page 192.

36. Huppe G, D Pepin, A Wakefield, Q Yang, BC Vanderhyden, C-W Chu and Z-Q Shao (2006). Over-expression of human tissue kallikreins decreases tumorigenicity of ovarian cancer cells in nude mice. AACR Meeting Abstracts, Apr 2006: 976.

37. Yang Q, G Huppe, C-W Chu, BC Vanderhyden and Z-Q Shao (2006). Kallikrein expression is associated with less aggressive phenotype in ovarian cancer cells. AACR Meeting Abstracts, Apr 2006: 974.

38. Pépin, D and BC Vanderhyden (2008). The ISWI protein Snf2l regulates multiple genes involved in the steroid biosynthesis pathway. Biol. Reprod. Special Issue, page 178.

39. Laviolette L, K Garson, E Macdonald, M Senterman, K Courville and B Vanderhyden (2008). Exogenous 17β-estradiol results in an earlier onset of ovarian cancer and a decreased survival time in a transgenic mouse model of ovarian cancer. Biol. Reprod. Special Issue, page 194.

40. Laviolette L, K Garson, N Minhas, E Macdonald, M Senterman, K Courville and B Vanderhyden (2009). Estrogen treatment induces preneoplastic lesions, accelerates tumor onset and decreases survival time in a transgenic mouse model of ovarian cancer. AACR Meeting Abstracts, Apr 2009: 295.

41. Yan FJ, I Steffensen, K Garson, BC Vanderhyden (2010). Therapeutic testing of a novel PKC inhibitor GAP-107B8 on ovarian cancer cells. AACR Meeting Abstracts, Apr 2010: 2536.

42. Yan FJ, K Garson, J Chabot and BC Vanderhyden (2011). Therapeutic testing of a novel inhibitor GAP-107B8 on ovarian cancer cells. AACR Meeting Abstracts, Apr 2011.

43. Turchet LF, O Collins and BC Vanderhyden (2011). Stem Cell Antigen-1 expression marks a population of mouse ovarian surface epithelial cells with enhanced stem/progenitor cell characteristics. Biol. Reprod. Special Issue, Volume 85, Abstract 55.

44. Hodgkinson K, L Laviolette, C Perez-Iratxeta and BC Vanderhyden (2011). Reproductive steroid hormones alter ovarian cancer progression in mouse models. Biol. Reprod. Special Issue, Volume 85, Abstract 343.

45. González Aguirre M, J Chabot, R So, LE Sancen Chaparro, FJ Yan, K Garson, B Vanderhyden and KK Sokoll. Novel liposomal compositions of PharmaGap’s lead peptide: Effect on ovarian cancer cell proliferation and signaling pathways. AACR Meeting Abstracts, Apr 2012.

46. Wardell JR, K Hodgkinson, KA Seymour, CW O’Brien, BC Vanderhyden and RN Freiman (2012). TAF4B is induced by estrogen in the normal mouse ovary and during estrogen-supplemented ovarian tumorigenesis. Biol. Reprod. Special Issue (published in August 2012)

47. Vuong N, E Macdonald, K Hodgkinson. L Laviolette, B Vanderhyden (2012). Mechanisms by which estrogen accelerates ovarian tumor initiation. Biol. Reprod. Special Issue (published in August 2012)

48. Gamwell L, O Collins, B Vanderhyden (2012). Ovulation-associated factors expand a population of sca-1 expressing progenitor cells in the mouse ovarian surface epithelium. Biol. Reprod. Special Issue (published in August 2012)

19

INVITED SEMINARS 1. Roswell Park Memorial Institute, Buffalo, New York, July 28, 1987. Embryonic survival of in vitro fertilized

oocytes given additional time for pre-implantation development.

2. The Jackson Laboratory, Bar Harbor, Maine, August 5, 1987. Factors affecting the in vitro maturation and fertilization of rat oocytes.

3. Mount Sinai Hospital Research Institute, Toronto, August 12, 1987. Embryonic survival of in vitro fertilized oocytes given additional time for pre-implantation development.

4. The Wistar Institute, Philadelphia, Pennsylvania, Sept. 2, 1987. Embryonic development and implantation of in vitro fertilized rat oocytes.

5. Ottawa Centre for Cancer Research, University of Ottawa, Ottawa, Ontario, June 22, 1990. Regulation of granulosa cell function by the oocyte.

6. Department of Physiology, University of Ottawa, Ottawa, Ontario, June 6, 1991. Role of the oocyte in the function and differentiation of granulosa cells.

7. Loeb Research Institute, Ottawa Civic Hospital, Ottawa, Ontario, April 8, 1992. Function of the c-kit protooncogene in the ovary.

8. Amgen Inc., Santa Monica, California, July 6, 1994. Expression pattern and hormonal regulation of KL in the rat ovary: A possible role in oocyte meiosis?

9. Faculté de médecine vétérinaire, Université de Montréal, October 25, 1994. Ovarian follicular development and steroidogenesis: Looking to the oocyte for guidance.

10. Bell High School, Ottawa, November, 1994. Women in Science workshop.

11. Serono International Symposium on the "Life cycle of the ovarian follicle", Fort Lauderdale, Florida, November 2-5, 1995. Follicular development: Looking to the oocyte for guidance.

12. Ottawa Board of Education, Ottawa. November 29, 1995. Showcase for Women in Science conference.

13. Department of Anatomy, University of Ottawa, Ottawa. February 7, 1996. Novel perspectives on the factors that control ovarian function.

14. Ottawa Stroke Consortium and Applied Research, Ottawa. February 26, 1996. Production of genetically-altered animals for the study of human diseases.

15. Department of Obstetrics & Gynecology, McGill University, Montreal. April 18, 1996. Role of the c-kit tyrosine kinase receptor in ovarian function and tumorigenesis.

16. Universita degli Studi di Teramo, Symposium on "Regulation of follicular environment and oocyte maturation", Giulianova, Italy, June 3-4, 1996. Oocyte-secreted factors regulate granulosa cell steroidogenesis.

17. Department of Radiation Oncology and Physics, Ottawa Civic Hospital, Ottawa. June 12, 1996. Role of the c-kit tyrosine kinase receptor in ovarian function and tumorigenesis.

18. Annual Meeting of the Society for the Study of Reproduction, Symposium on “Gonadal Function: Novel Genes”, London, Ontario, July 27-30, 1996. Regulation of granulosa cell activity by the oocyte”

19. Departments of Pharmacology and Physiology, University of Ottawa, Ottawa. November 19, 1996. The Kit tyrosine kinase receptor: Exploration of its role in ovarian function and tumorigenesis.

20. Ottawa Board of Education, Ottawa. November 20, 1996. Showcase for Women in Science conference.

21. Department of Radiation Oncology and Physics, Ottawa Civic Hospital, Ottawa. April 23, 1997. Characterizing the ovarian surface epithelium: On the road to understanding ovarian cancer.

22. Canadian Society for the Weizmann Institute of Science, Ottawa. June 24, 1997. Playing with eggs, sperm and DNA: Is it wisdom or folly?

23. London Regional Cancer Centre, London. October 30, 1997. The Kit tyrosine kinase receptor: Exploring its role in ovarian function and ovarian cancer.

20

24. Genesis Research Foundation (fund-raising breakfast), Royal York Hotel, Toronto. November 6, 1997. Current advances in ovarian cancer research.

25. Loeb Research Institute, Ottawa. November 17, 1997. The Kit tyrosine kinase receptor: Exploring its role in ovarian function and ovarian cancer.

26. Department of Obstetrics and Gynecology Grand Rounds, University of Ottawa, Ottawa. November 19, 1997. Investigating the link between ovulation and ovarian cancer.

27. Ottawa General Hospital Research Institute, Ottawa. June 24, 1998. Characterizing the ovarian surface epithelium: On the road to understanding ovarian cancer.

28. American Society for Reproductive Medicine, Post-graduate course on “Human Conception from Oocyte to Blastocyst and Implantation”, October 3-4, 1998. Three lectures: Initiation of follicular growth; Oocyte maturation in vitro; Germ cell-somatic cell interactions.

29. Cornell University, Ithaca, New York. November 4, 1998. The Kit tyrosine kinase receptor: Exploring its role in ovarian function and ovarian cancer.

30. University of Western Ontario, London, Ontario. March 1, 1999. The Kit tyrosine kinase receptor: Exploring its role in ovarian function and ovarian cancer.

31. University of Ottawa Women in Science and Engineering (WISE), Ottawa, Ontario. Panel on “Successful Women in Science and Engineering at the University of Ottawa”, March 8, 1999.

32. American Society for Reproductive Medicine, Post-graduate course on “Hot Topics in Reproductive Medicine”, September 26, 1999. Lecture: Assessing Oocyte Quality.

33. Graduate Research Day, University of Western Ontario, London, Ontario. October 7, 1999. Life after grad school: How one Western grad survived the first 10 years.

34. Queen’s University, Kingston, Ontario. October 21, 1999. Role of the Kit tyrosine kinase receptor in ovarian cancer.

35. Ottawa Regional Cancer Centre Oncology Grand Rounds. October 28, 1999. Translational Research: Combining basic research and clinical perspectives in the study of ovarian cancer.

36. University of South Florida and Moffitt Cancer Center, Tampa, Florida. March 22-23, 2000. Role of the Kit tyrosine kinase receptor in ovarian cancer.

37. Endocrine Society’s Annual Meeting, Symposium on Oocyte Development, Toronto, Ontario, June 21-24, 2000. Molecular control of oocyte growth and maturation.

38. Canadian Association for Lab Animal Sciences Annual Meeting, Ottawa, Ontario. June 26, 2000. Generation and care of transgenic animals.

39. Canadian Association for Lab Animal Sciences Annual Meeting, Ottawa, Ontario. June 27, 2000. Ethics of generating genetically modified animals.

40. Arizona State University, Tempe, Arizona. February 12, 2001. Cellular and molecular control of oocyte growth and maturation.

41. Université de Montréal, Montréal, Québec. April 17, 2001. Characterizing the ovarian surface epithelium: On the road to understanding ovarian cancer

42. Queen’s University, Kingston, Ontario. November 6, 2001. Characterizing the ovarian surface epithelium and targetting gene expression to generate mouse models of ovarian cancer.

43. Ontario Cancer Institute/Princess Margaret Hospital, Toronto, Ontario. February 7, 2002. Targetting gene expression to generate mouse models of ovarian cancer.

44. Serono Reproductive Biology Institute Inc., Boston, Massachusetts. February 15-17, 2002. Cellular and molecular mechanisms controlling oocyte and follicle development.

45. Canadian Conference on Ovarian Cancer Research, Ottawa, Ontario. May 27-28, 2002. Gleevec inactivation of KIT oncoprotein in ovarian cancer cells: Biological and clinical implications.

21

46. Sunnybrook Hospital, Molecular & Cell Biology, Toronto, Ontario. June 19, 2002. Targetting gene expression to generate mouse models of ovarian cancer.

47. University of Calgary, Cancer Biology Research Group, Calgary, Alberta. June 27, 2002. Targetting gene expression to generate mouse models of ovarian cancer.

48. University of Calgary, Alberta Heritage Foundation for Medical Research Special Seminar, Calgary, Alberta. June 27, 2002. Let’s Talk Science: The benefits of science promotion.

49. Gordon Research Conference, New London, Connecticut. June 30 – July 5, 2002. Differential expression of Snf2h and Snf2l correlates with changes in granulosa cell proliferation and differentiation.

50. Serono Ovarian Workshop, Baltimore, Maryland. July 25-27, 2002. Cell-specific targeting for the generation of mouse models of ovarian cancer.

51. Symposium on Reproduction in Domestic Ruminants, Crieff, Scotland. August 14-17, 2002. The role of the oocyte during folliculogenesis.

52. Canadian Fertility and Andrology Society Annual Meeting. September 25-28, 2002. Characterizing the ovarian surface epithelium: On the road to understanding ovarian cancer.

53. Dalhousie University, Department of Pharmacology, Halifax. November 8, 2002. Biological and clinical implications of Gleevec inactivation of KIT oncoprotein in ovarian cancer cells.

54. DIVA Foundation, Ottawa. November 27, 2002. The pros and cons of having ovaries: What you need to know about ovarian cancer.

55. Northwestern University, Department of Neurobiology and Physiology, Evanston, Illinois. January 21, 2003. Cell-specific targeting for the generation of mouse models of ovarian cancer.

56. International Women’s Day Symposium on “Ovaries over the ages: Ovarian Cancer, Increasing Awareness”, Ottawa. March 4, 2003. The future for ovarian cancer patients: How can ovarian cancer research help?

57. 11E Rencontre Hivernale des Biologistes en Reproduction du Québec, Forêt Montmorency, Québec. March 9-12, 2003. Paracrine factors that mediate oocyte-granulosa cell interactions.

58. Georgetown University, Washington, D.C. April 10, 2003. Cell-specific targeting for the generation of mouse models of ovarian cancer.

59. Ottawa Reproductive Biology Workshop, Ottawa. May 12, 2003. Targeting the ovarian surface epithelium to generate mouse models of ovarian cancer.

60. Annual Meeting of the Society for the Study of Reproduction, Symposium on “Chromatin modification and epigenetic regulation in the ovary”, Cincinnati, Ohio, July 19-22, 2003. Role of ISWI chromatin remodeling proteins in granulosa cell differentiation”.

61. Centre de recherche Guy-Bernier, Hôpital Maisonneuve-Rosemont, Montréal. September 26, 2003. Targeting the ovarian surface epithelium to generate mouse models of ovarian cancer.

62. Canadian Fertility and Andrology Society, Victoria, British Columbia. November 5-8, 2003. Granulosa cells and the acquisition of oocyte developmental competence.

63. Department of Cellular and Molecular Medicine, University of Ottawa. November 11, 2003. Ovarian cancer: Targeted therapeutics and mouse models.

64. Institut national de la recherche scientifique - Institut Armand Frappier, Pointe Claire Québec. November 27, 2003. Targeting gene expression in the ovary to generate mouse models of ovarian cancer.

65. Mouse Models of Gynecologic Cancers Meeting, National Cancer Institute, San Juan, Puerto Rico. February 17-20, 2004. Is germ cell deficiency a factor in ovarian tumorigenesis?

66. Canadian Workshop on Human Reproduction and Reproductive Biology, Ottawa. May 3-4, 2004. Building animal models of ovarian cancer for the testing of novel therapeutics.

67. Canadian Conference on Ovarian Cancer Research, Ottawa. May 16-18, 2004. Biology of ovarian cancer: Choice and influence of the model system.

22

68. 1st World Congress on In Vitro Maturation, Montréal. October 15, 2004. Oocyte growth in the ovary.

69. Canada-Japan Bilateral Workshop, Ottawa. November 29-December 1, 2004. Animal models for human ovarian cancer research.

70. Ottawa Health Research Institute, Loeb seminar series. December 6, 2004. Targeting the ovarian surface epithelium for the generation of models of ovarian cancer.

71. Guangxi Cancer Hospital, Nanning, China. April 27, 2005. Investigation of Gleevec as a therapeutic drug for ovarian cancer.

72. Biotechnology Lecture Series, Museum of Science and Technology, May 3, 2005. Assisted Reproduction Technologies. Playing with Eggs and Sperm: Is it wisdom or folly?

73. Department of Pathology and Laboratory Medicine, Annual Research Day. May 11, 2005. Mouse models of ovarian cancer – getting the pathology right.

74. National Ovarian Cancer Association, Ovarian Cancer Symposium, Niagara Falls. June 4, 2005. Emerging Therapies: Where do we go from here?

75. Update in Gynecologic Malignancy: Ovarian Cancer, Division of Gynecologic Oncology, London Health Sciences Centre / The University of Western Ontario. September 16, 2005. From tissues to trials: Translating basic research of ovarian cancer into clinical application.

76. New Targets for Cancer Prevention and Therapy, 9th Meeting of the Hirosaki International Forum of Medical Science. Hirosaki, Japan. November 10-11, 2005. Mouse models for human ovarian cancer research

77. First Sino-Canada Bilateral Workshop on Reproductive Health Research, Beijing, China. November 15-18, 2005. Mouse models for human ovarian cancer research

78. Canadian Cancer Society, Ottawa Unit Residential Volunteers. January 22, 2006. The future for ovarian cancer patients: How can research help?

79. Department of Biology Annual Research Day, April 4, 2006. The pros and cons of having ovaries: On the road to understanding ovarian cancer.

80. Biotechnology Lecture Series, Museum of Science and Technology, May 2, 2006. Assisted Reproduction Technologies. Playing with Eggs and Sperm: Is it wisdom or folly?

81. National Ovarian Cancer Association, Ovarian Cancer Symposium, Windsor, Ontario. May 6, 2006. Ovarian Cancer Research: What's going on in Canada?

82. Public Lecture at Sir Robert Borden High School, Ottawa. May 11, 2006. Cancer: What we know and how we treat it.

83. National Ovarian Cancer Association, Ovarian Cancer Symposium, Vancouver. May 13, 2006. Ovarian Cancer Research: What's going on in Canada?

84. 3rd Canadian Conference on Ovarian Cancer Research, Vancouver. May 13-16, 2006. Is there an ovarian surface epithelial stem cell?

85. Hormonally-Induced Reproductive Tumors: Relevance of Rodent Bioassays. National Toxicology Program, National Institute of Environmental Health Sciences, NIH, Raleigh, North Carolina. May 21-24, 2006. Mouse models of ovarian cancer: Model development.

86. Serono Symposium for Laboratory, Embryology and Andrology Professionals (LEAP), Mississauga, Ontario. June 9-11, 2006. Physiology and Endocrinology of the Female Reproductive System.

87. Marsha Rivkin Ovarian Cancer Research Symposium, Seattle, Washington. September 7-8, 2006. Mouse models of ovarian cancer: Generation and validation for pre-clinical testing of novel therapeutics.

88. Memorial University, St. John's, Newfoundland. November 3, 2006. Mouse models for ovarian cancer research.

89. University of California at San Diego, February 5, 2007. Hormonal regulation of paracrine factors controlling oocyte and follicle growth.

23

90. University of California at San Diego, February 5, 2007. Generation of mouse models of ovarian cancer to study disease etiology.

91. Biotechnology Lecture Series, Museum of Science and Technology, May 1, 2007. Assisted Reproduction Technologies. Playing with Eggs and Sperm: Is it wisdom or folly?

92. Fourth Canada-Japan Bilateral Workshop on Human Reproduction and Reproductive Biology, Hirosaki University, Japan, July 31– August 2, 2007. Testing of novel treatment strategies for ovarian cancer.

93. Second Sino-Canada Bilateral Workshop on Reproductive Health Research, University of Ottawa, October 19-21, 2007. Transformation of mouse ovarian surface epithelium into ovarian cancer.

94. University of South Florida, Tampa, April 4, 2008. Generation of mouse models of ovarian cancer to study disease etiology and for pre-clinical testing of novel therapeutics.

95. Radiation Oncology/Physics Rounds, Ottawa Hospital Regional Cancer Centre, June 4, 2008. Generation of mouse models of ovarian cancer to study disease etiology and for therapeutic testing.

96. Gordon Research Conference on Reproductive Tract Biology, Andover, New Hampshire. August 3-8, 2008. Mouse models of ovarian cancer.

97. Department of Physiology and Pharmacology, University of Western Ontario, London. August 21, 2008. How to make a good egg: Factors that regulate ovarian follicle development.

98. Department of Anatomy and Physiology, Kansas State University, Manhattan, Kansas. February 2, 2009. Generation of mouse models of ovarian cancer to study disease etiology.

99. Café scientifique. Fox and Feather Pub, Ottawa. April 28, 2009. Are designer babies the way to a healthier future?

100. Women's Health: Research Today for Tomorrow’s Therapies. May 7, 2009. Seminar and panel discussion organized by the Hebrew University of Jerusalem's Institute for Medical Research and the Ottawa Hospital Research Institute. Properties of ovarian cancer cells that contribute to their potential to metastasize.

101. University of Ontario Institute of Technology. August 18, 2009. Mouse models of ovarian cancer to study disease etiology and for therapeutic testing.

102. Laurentian University, Sudbury, Ontario. October 20, 2009. Mouse models of ovarian cancer to study disease etiology and for therapeutic testing.

103. University of South Dakota, Vermillion, South Dakota. November 13, 2009. Mouse models of ovarian cancer to study disease etiology and for therapeutic testing.

104. Brown University, Providence, Rhode Island. February 5, 2010. Generation of mouse models of ovarian cancer to study disease etiology.

105. The X Factor: Women in Biology and the Biology of Women. York University, Toronto. March 5, 2010. Symposium organized by the Association of Graduate Students in the Biological Sciences. Mouse models of ovarian cancer to study disease etiology and for therapeutic testing.

106. University of Chicago, Chicago. April 16, 2010. Generation of mouse models of ovarian cancer to study disease etiology and for therapeutic testing.

107. Biotechnology Lecture Series, Museum of Science and Technology, May 6, 2010. Assisted Reproduction Technologies. Playing with Eggs and Sperm: Is it wisdom or folly?

108. Ovarian Workshop, Milwaukee, Wisconsin. July 28-30, 2010. Transformation of mouse ovarian surface epithelium into cancer.

109. University of Georgia, Athens, Georgia. February 16, 2011. Exploring how normal cells become cancer in the ovary.

110. Morehouse School of Medicine, Atlanta, Georgia. February 17, 2011. Exploring how normal cells become cancer in the ovary.

111. Morehouse School of Medicine, Atlanta, Georgia. February 17, 2011. Let's Talk Science: The benefits of

24

science outreach.

112. Ovarian Cancer Canada, Toronto. February 23, 2011. Research update on ovarian cancer (delivered by teleconference and posted on www.youtube.com/OvarianCancerCanada).

113. Department of Anatomy and Cell Biology, University of Western Ontario, London, Ontario. April 8, 2011. Exploring how normal cells become cancer in the ovary.

114. Biotechnology Lecture Series, Museum of Science and Technology, May 5, 2011. Assisted Reproduction Technologies. Playing with Eggs and Sperm: Is it wisdom or folly?

115. 30th Annual University of Kentucky Symposium in Reproductive Science and Women's Health, Lexington, Kentucky. May 19-20, 2011. Mouse models of ovarian cancer to study disease etiology and for therapeutic testing.

116. Annual Meeting of the Society for the Study of Reproduction, Portland, Oregon. July 29-August 1, 2011. Lessons learned from mouse models of ovarian cancer.

117. Le Centre de Recherche de L’Hôtel-Dieu de Québec, Québec City. January 13, 2012. Lessons learned from mouse models of ovarian cancer.

118. Institut du cancer de Montréal, Montréal. March 28, 2012. Exploring how normal cells become cancer in the ovary.

119. University of Kansas Medical Center, Kansas City, Missouri. April 26, 2012. The etiology of ovarian cancer: Lessons learned from mouse models

120. Biotechnology Lecture Series, Museum of Science and Technology, May 9, 2012. Assisted Reproduction Technologies. Playing with Eggs and Sperm: Is it wisdom or folly?

121. Canadian Conference on Ovarian Cancer Research, Québec City. May 27-29, 2012. Ovulation-associated factors promote stem/progenitor cell characteristics in ovarian surface epithelial cells: A starting point for ovarian cancer?

122. Marsha Rivkin Center’s 9th Biennial Ovarian Cancer Research Symposium, Seattle University, Seattle, Washington. September 6-7, 2012. Role of PAX2 in the etiology of ovarian and fallopian tube cancers.

123. Leading the Way, Lighting the Way, Canadian Cancer Society Leadership Conference, Perth, ON. October 27, 2012. The impact of cancer research.

124. Ovarian Cancer and You; Patient Education Day organized by Ovarian Cancer Canada and the Ottawa Regional Cancer Foundation. Maplesoft Centre, Nov. 26, 2012. Looking forward: What's new in ovarian cancer research?

125. Ovarian Cancer Canada, Toronto. January 28, 2013. The Challenges of Ovarian Cancer.

126. University of Chicago at Urbana-Champaign, Champaign, Illinois. April 19, 2013. Stem cells in the ovary: Is this why ovulation is a risk factor for ovarian cancer?

127. South Illinois University, Carbondale, Illinois. April 26, 2013. Stem cells in the ovary: Is this why ovulation is a risk factor for ovarian cancer?

128. Canadian Cancer Society, Ottawa. May 23, 2013. What is cancer and what are we doing about it?

129. University of Ottawa Workshop on Women’s Reproductive Health Research, Ottawa. June 4, 2013. Ovarian Stem Cells: A possible link between hereditary and non-hereditary risks of ovarian cancer.

130. Department of Biochemistry, University of Alberta, Edmonton. June 28, 2013. The Etiology of Ovarian Cancer: Lessons learned from mouse models.

131. Cornell University, Ithaca, New York, October 2, 2013. Stem cells in the ovary: Is this why ovulation is a risk factor for ovarian cancer?

132. National Science and Tech Week Lectures, Museum of Science and Technology, October 22, 2013. Assisted Reproduction Technologies. Playing with Eggs and Sperm: Is it wisdom or folly?

133. Annual Symposium of the Réseau Québécois en reproduction, St. Hyacinthe, QC. November 11-13, 2013. Stem

25

cells in the ovary: Is this why ovulation is a risk factor for ovarian cancer?

134. Living and Thriving Conference, Regina, Saskatchewan. December 6-7, 2013. Looking Forward: What’s new in ovarian cancer research.

135. Ottawa Regional Cancer Foundation, Ottawa. March 4, 2014. Importance of cancer research: Translating lab research into clinical trials.

136. Ovarian Cancer Survivors’ Symposium, Victoria, British Columbia. May 25, 2014. New understandings of ovarian cancer.

137. Canadian Council of Deans of Science, Ottawa. June 16, 2014. Science Education and First Nations Students.

138. Canadian Association of Laboratory Animal Sciences, Ottawa. June 17, 2014. Mythbusters: The importance of science outreach.

EDUCATIONAL WORKSHOPS DELIVERED 1. Graduate Student Ethics Workshop. March 18, 2005. Seminar on Research Ethics.

2. Centre for University Teaching, University of Ottawa. September 6, 2008. Effective Communication: Why and how to share your knowledge and research with others. (50 student participants)

3. Faculty of Medicine Research Ethics Day. November 28, 2008. Seminar on Plagiarism.

4. University of Ottawa Faculty of Graduate and Postdoctoral Studies. Workshop on Graduate Supervision. March 25, 2009. (40 faculty members)

5. Workshop for Postdoctoral Fellow Association. May 28, 2009. How to prepare for a job interview.

6. University of Ontario Institute of Technology. August 18, 2009. Workshop on Graduate Supervision. (30 faculty members)

7. University of Ottawa Faculty of Graduate and Postdoctoral Studies. Workshop on Graduate Supervision. January 7, 2010. (50 faculty members)

8. University of Ottawa Centre for Academic Leadership. Workshop on Communications, panel member. April 22, 2010.

9. Faculty of Medicine Research Ethics Day. April 23, 2010. Seminar on Plagiarism.

10. University of Ottawa Faculty of Graduate and Postdoctoral Studies. Workshop on Graduate Supervision. December 15, 2010. (30 faculty members)

11. Faculty of Medicine Research Ethics Day. September 17, 2010. Seminar on Plagiarism.

12. Workshops for Postdoctoral Fellow Association. January 21, 2011. How to prepare a CV to apply for an academic position.

13. University of Ottawa Faculty of Graduate and Postdoctoral Supervision. Workshop on Graduate Supervision. April 20, 2011. (20 faculty members)

14. Navigating your PATH conference. University of Toronto, May 5-7, 2011. Chair for Panel Session on ‘Improving Communication Skills through Science Outreach’, Seminar on ‘Graduate course on community outreach and media relations in the sciences’.

15. Faculty of Medicine Research Ethics Day. September 23, 2011. Seminar on Plagiarism.

16. University of Ottawa Faculty of Graduate and Postdoctoral Studies. Workshop on Graduate Supervision. April 23, 2012. (25 faculty members)

17. Faculty of Medicine Research Ethics Day. September 28, 2012. Seminar on Plagiarism.

18. Faculty of Medicine Research Ethics Day. October 4, 2013. Seminar on Plagiarism.

19. The Arthritis Society/Canadian Arthritis Network Trainee Workshop. November 24, 2013. Community Outreach and Media Relations.

26

PRESENTATIONS AT CONFERENCES and LOCAL MEETINGS (past 15 years only) 1. Gordon Research Conference, Plymouth State College, Plymouth, New Hampshire, July 5-10, 1998. Hormonal

regulation of kit ligand may modulate its effects on oocyte development.

2. Canadian Fertility and Andrology Society, Mont Tremblant, September 9-12, 1998. Hormonal regulation of kit ligand may modulate its effects on oocyte maturation.

3. Department of Obstetrics and Gynecology Staff Research Day, University of Ottawa, Ottawa, Ontario, October 14, 1998. Developing a non-invasive test to assess the developmental capacity of human embryos.

4. Northeastern Regional Developmental Biology Conference, Woods Hole, Massachusetts, March 12, 1999. Mouse oocytes regulate granulosa cell steroidogenesis throughout follicular development.

5. Department of Obstetrics and Gynecology Staff Research Day, University of Ottawa, Ontario, October 27, 1999. Epithelial-stromal cell interactions at ovulation: Investigating ovulation as a risk factor for ovarian cancer.

6. Cancer Care Ontario Research Conference, Lake Couchiching, Ontario, November 8-10, 1999. Lack of expression of the c-kit protooncogene in epithelial ovarian cancers is associated with poor prognosis.

7. Department of Obstetrics and Gynecology Staff Research Day, University of Ottawa, Ottawa, Ontario, October 24, 2001. c-Kit expression in ovarian cancers is attributable to E-cadherin expression and is associated with well-differentiated tumours and improved patient prognosis.

8. Ottawa Regional Cancer Centre, Research and Development Rounds, June 12, 2002. Teamwork and tumour banks: Exploiting the potential.

9. Department of Obstetrics and Gynecology Staff Research Day, University of Ottawa, Ottawa, Ontario, October 23, 2002. Targeting gene expression to the ovarian surface epithelium for the generation of mouse models of ovarian cancer.

10. Ottawa Reproductive Biology Workshop, Ottawa. May 12, 2003. Targeting the ovarian surface epithelium to generate mouse models of ovarian cancer.

11. Department of Obstetrics and Gynecology Staff Research Day, University of Ottawa, Ottawa, Ontario, October 22, 2003. Molecular mechanisms contributing to oocyte and follicle growth.

12. Department of Obstetrics and Gynecology Staff Research Day, University of Ottawa, Ottawa, Ontario, October 20, 2004. Gleevec decreases proliferation and survival of ovarian cancer cells and may sensitize chemoresistant cells to cisplatin.

13. Ottawa Regional Cancer Centre, Research and Development Rounds, November 10, 2004. Gynecologic Oncology Research: From Tissues to Trials.

14. Canadian Council on Animal Care Workshop on Genetically Modified Animals, April 12-13, 2005. Wellness assessment of genetically modified animals.

15. Ottawa Health Research Institute Scientist Retreat, April 14-15, 2005. Modeling human ovarian cancer in mice.

16. Department of Obstetrics and Gynecology Staff Research Day, University of Ottawa, Ottawa, Ontario, October 19, 2005. The role of the BRCA1 gene in the transformation of the mouse ovarian surface epithelium.

17. Ottawa Reproductive Biology Workshop, Ottawa. May 14, 2008. Testing novel treatment strategies for ovarian cancer.

18. Ottawa Reproductive Biology Workshop, Ottawa. June 17, 2011. Roles of Pax genes in the origin of ovarian and fallopian tube cancers.

19. Ottawa Hospital Research Institute Scientists’ Retreat, Ottawa. May 30, 2012. The origins of ovarian cancer.

27

OUTREACH ACTIVITIES AND MENTORSHIP 1) Promoting Awareness of Ovarian Cancer As the Corinne Boyer Chair in Ovarian Cancer Research, I have done extensive outreach (88 events) to raise awareness about ovarian cancer during the past five years. My community activities have included: - Speaker at >25 ovarian cancer educational and fund-raising events in the Ottawa region - 24 public lectures for various organizations, including Ovarian Cancer Canada, the Canadian Cancer Society,

the Ottawa Regional Cancer Foundation and the Ottawa Hospital Foundation - Speaker in the DIVA Foundation series on Women's Health (Healthy World). Seminar title: "The pros and

cons of having ovaries: What you need to know about ovarian cancer" - Wrote a cancer blog for a week for the Ottawa Regional Cancer Foundation - My research group was the focus of several articles in various newspapers and magazines, including a 2-page

article in the Ottawa Citizen - Interviewed for 30 print, television and radio programs/organizations about her research program by local and

national media leading to 9 articles published in newspapers and magazines across Canada (eg. Ottawa Citizen, Ottawa Sun, Globe and Mail, Homemakers, Canadian Living)

- Contributor to a number of articles for the "Seeds of Hope" newsletter or E-news (electronic newsletter) of Ovarian Cancer Canada

- Preparation of detailed annual progress reports for sponsors and supporters of the ovarian cancer research program - Creation of a website that informs the public about the Corinne Boyer Chair and the ovarian cancer research

program (www.med.uottawa.ca/vanderhyden/) 2) Improving Science Literacy among Young People In Ottawa: In 1993, I established the science outreach program Let’s Talk Science-Parlons sciences at the University of Ottawa (http://letstalkscience.ca/ottawa/). Initially it was simply the parallel of an outreach program that I was involved in as a graduate student at the University of Western Ontario. However, Let's Talk Science is now a national charitable organization with a mandate to improve science literacy, and the only national graduate student-driven science outreach program in the world. Under my direction, the Ottawa chapter has grown and thrived and now runs jointly with students from Carleton University. Currently, 325 university graduate students volunteer to bring hands-on science workshops to elementary and secondary school students. In the past year alone the Let's Talk Science program in Ottawa delivered 500 science workshops to almost 16,000 elementary and high school students. Offered as a free and bilingual service to all science teachers in the Ottawa region, Let's Talk Science is a unique opportunity for teachers to provide fun and interactive learning experiences for their students, while at the same time providing opportunities for young scientists-in-training to acquire the skills to speak publicly about their research and to serve as role models for the pre-university students. We have expanded our reach internationally – with our first team of 3 volunteers spending one month in Tanzania in October 2009, a second team traveled to Ethiopia in early 2010, and team have since delivered workshops in Brazil and Thailand. As Director of the Let's Talk Science program in Ottawa, my responsibilities include: soliciting financial support, recruiting and training the program coordinators, overseeing the training of the program's volunteers, and assisting with the development of the science workshops to ensure that they are age-appropriate, educational and fun. The program is currently managed by a 0.5 FTE Science Outreach Program Manager and 5 part-time graduate student coordinators. In remote and aboriginal communities: In 2006, I expanded the Let's Talk Science program into new directions by establishing Science Travels – La science voyage - a program that delivers science workshops to remote and aboriginal communities in northern Ontario, Nunavut and the Northwest Territories (www.sciencetravels.uottawa.ca). In its first term, the program delivered 68 workshops on 17 different science topics at 13 high schools and native Friendship Centres - surpassing all expectations of the success of this program. Each May, 24 of the brightest Grade 11 students with aptitudes for science from those schools and Friendship Centres are invited to Ottawa for a week. For this event, we create a program of lab activities, presentations by leading-edge researchers, student mentorship and social activities designed to encourage and motivate the interest in science and science education in these young students. To maintain our support of these students, we established an Aboriginal Mentorship Program that continues throughout the year. Science Travels is now in its seventh year and funded by NSERC PromoScience and CIHR Synapse grants. It continues to grow in both its reach and impact, with 10-12 teams traveling to the north to deliver more than 125 workshops each year. The program is managed by a 0.5 FTE Science Outreach Program Manager.